TY - JOUR AU - Arya, Shristi AU - Bahuguna, Deepankar AU - Bajad, Gopal AU - Loharkar, Soham AU - Devangan, Pawan AU - Khatri, Dharmendra Kumar AU - Singh, Shashi Bala AU - Madan, Jitender TI - Colloidal therapeutics in the management of traumatic brain injury: Portray of biomarkers and drug-targets, preclinical and clinical pieces of evidence and future prospects JF - COLLOIDS AND SURFACES B: BIOINTERFACES J2 - COLLOID SURFACE B VL - 230 PY - 2023 PG - 13 SN - 0927-7765 DO - 10.1016/j.colsurfb.2023.113509 UR - https://m2.mtmt.hu/api/publication/34338789 ID - 34338789 N1 - Funding Agency and Grant Number: Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, New Delhi, India Funding text: Authors are highly thankful to the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, New Delhi, India for providing financial assistance. AB - Complexity associated with the aberrant physiology of traumatic brain injury (TBI) makes its therapeutic targeting vulnerable. The underlying mechanisms of pathophysiology of TBI are yet to be completely illustrated. Primary injury in TBI is associated with contusions and axonal shearing whereas excitotoxicity, mitochondrial dysfunction, free radicals generation, and neuroinflammation are considered under secondary injury. MicroRNAs, proinflammatory cytokines, and Glial fibrillary acidic protein (GFAP) recently emerged as biomarkers in TBI. In addition, several approved therapeutic entities have been explored to target existing and newly identified drug-targets in TBI. However, drug delivery in TBI is hampered due to disruption of blood-brain barrier (BBB) in secondary TBI, as well as inadequate drug-targeting and retention effect. Colloidal therapeutics appeared helpful in providing enhanced drug availability to the brain owing to definite targeting strategies. Moreover, immense efforts have been put together to achieve increased bioavailability of therapeutics to TBI by devising effective targeting strategies. The potential of colloidal therapeutics to efficiently deliver drugs at the site of injury and down-regulate the mediators of TBI are serving as novel policies in the management of TBI. Therefore, in present manuscript, we have illuminated a myriad of molecular-targets currently identified and recognized in TBI. Moreover, particular emphasis is given to frame armamentarium of repurpose drugs which could be utilized to block molecular targets in TBI in addition to drug delivery barriers. The critical role of colloidal therapeutics such as liposomes, nanoparticles, dendrimers, and exosomes in drug delivery to TBI through invasive and non-invasive routes has also been highlighted. LA - English DB - MTMT ER - TY - JOUR AU - Bagnato, Sergio AU - Boccagni, Cristina TI - Cerebrospinal Fluid and Blood Biomarkers in Patients with Post-Traumatic Disorders of Consciousness: A Scoping Review JF - BRAIN SCIENCES J2 - BRAIN SCI VL - 13 PY - 2023 IS - 2 PG - 10 SN - 2076-3425 DO - 10.3390/brainsci13020364 UR - https://m2.mtmt.hu/api/publication/33868396 ID - 33868396 N1 - Cited By :2 Export Date: 1 February 2024 Correspondence Address: Bagnato, S.; Unit of Neurophysiology and Unit for Severe Acquired Brain Injuries, viale G. Giardina, PA, Italy; email: sergiobagnato@gmail.com AB - (1) Background: Cerebrospinal fluid (CSF) and blood biomarkers are emerging tools used to obtain information on secondary brain damage and to improve diagnostic and prognostic accuracy for patients with prolonged post-traumatic disorders of consciousness (DoC). We synthesized available data from studies evaluating CSF and blood biomarkers in these patients. (2) Methods: A scoping review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist to identify and synthesize data from relevant studies. Studies were identified by PubMed and manual searches. Those involving patients with unresponsive wakefulness syndrome or in a minimally conscious state for >28 days, evaluating CSF or blood biomarkers, and conducted on patients with traumatic brain injuries older than 16 years were included in the review. (3) Results: In total, 17 studies were included. Findings on neurofilament light chain, proteins, metabolites, lipids, amyloid-beta, tau, melatonin, thyroid hormones, microtubule-associated protein 2, neuron-specific enolase, and brain-derived neurotrophic factor were included in the qualitative synthesis. (4) Conclusions: The most promising applications for CSF and blood biomarkers are the monitoring of secondary neurodegeneration, support of DoC diagnoses, and refinement of prognoses, although current evidence remains too scarce to recommend such uses of these biomarkers in clinical practice. LA - English DB - MTMT ER - TY - JOUR AU - Fesharaki-Zadeh, Arman TI - Navigating the Complexities of Traumatic Encephalopathy Syndrome (TES): Current State and Future Challenges JF - BIOMEDICINES J2 - BIOMEDICINES VL - 11 PY - 2023 IS - 12 PG - 21 SN - 2227-9059 DO - 10.3390/biomedicines11123158 UR - https://m2.mtmt.hu/api/publication/34555465 ID - 34555465 N1 - Export Date: 6 February 2024 Correspondence Address: Fesharaki-Zadeh, A.; Department of Neurology and Psychiatry, United States; email: arman.fesharaki@yale.edu AB - Chronic traumatic encephalopathy (CTE) is a unique neurodegenerative disease that is associated with repetitive head impacts (RHI) in both civilian and military settings. In 2014, the research criteria for the clinical manifestation of CTE, traumatic encephalopathy syndrome (TES), were proposed to improve the clinical identification and understanding of the complex neuropathological phenomena underlying CTE. This review provides a comprehensive overview of the current understanding of the neuropathological and clinical features of CTE, proposed biomarkers of traumatic brain injury (TBI) in both research and clinical settings, and a range of treatments based on previous preclinical and clinical research studies. Due to the heterogeneity of TBI, there is no universally agreed-upon serum, CSF, or neuroimaging marker for its diagnosis. However, as our understanding of this complex disease continues to evolve, it is likely that there will be more robust, early diagnostic methods and effective clinical treatments. This is especially important given the increasing evidence of a correlation between TBI and neurodegenerative conditions, such as Alzheimer's disease and CTE. As public awareness of these conditions grows, it is imperative to prioritize both basic and clinical research, as well as the implementation of necessary safe and preventative measures. LA - English DB - MTMT ER - TY - JOUR AU - Harris, Georgia AU - Rickard, Jonathan James Stanley AU - Butt, Gibran AU - Kelleher, Liam AU - Blanch, Richard James AU - Cooper, Jonathan AU - Oppenheimer, Pola Goldberg TI - Review: Emerging Eye-Based Diagnostic Technologies for Traumatic Brain Injury JF - IEEE REVIEWS IN BIOMEDICAL ENGINEERING J2 - IEEE REV BIOMED ENG VL - 16 PY - 2023 IS - 1 SP - 530 EP - 559 PG - 30 SN - 1937-3333 DO - 10.1109/RBME.2022.3161352 UR - https://m2.mtmt.hu/api/publication/33858664 ID - 33858664 N1 - Funding Agency and Grant Number: Wellcome Trust [174ISSFPP]; Royal Academy of Engineering [RF1415\14\28]; Defence Science and Technology Laboratories [DSTLX-1000098511]; EPSRC [EP/V029983/1] Funding text: This work was supported in part by the Wellcome Trust under Grant 174ISSFPP, in part by the Royal Academy of Engineering under Grant RF1415\14\28, in part by the Defence Science and Technology Laboratories under Grant DSTLX-1000098511, and also in part by the financial support of this work by the EPSRC under Grant EP/V029983/1. AB - The study of ocular manifestations of neurodegenerative disorders, Oculomics, is a growing field of investigation for early diagnostics, enabling structural and chemical biomarkers to be monitored overtime to predict prognosis. Traumatic brain injury (TBI) triggers a cascade of events harmful to the brain, which can lead to neurodegeneration. TBI, termed the "silent epidemic" is becoming a leading cause of death and disability worldwide. There is currently no effective diagnostic tool for TBI, and yet, early-intervention is known to considerably shorten hospital stays, improve outcomes, fasten neurological recovery and lower mortality rates, highlighting the unmet need for techniques capable of rapid and accurate point-of-care diagnostics, implemented in the earliest stages. This review focuses on the latest advances in the main neuropathophysiological responses and the achievements and shortfalls of TBI diagnostic methods. Validated and emerging TBI-indicative biomarkers are outlined and linked to ocular neuro-disorders. Methods detecting structural and chemical ocular responses to TBI are categorised along with prospective chemical and physical sensing techniques. Particular attention is drawn to the potential of Raman spectroscopy as a non-invasive sensing of neurological molecular signatures in the ocular projections of the brain, laying the platform for the first tangible path towards alternative point-of-care diagnostic technologies for TBI LA - English DB - MTMT ER - TY - JOUR AU - Khetani, S. AU - Salahandish, R. AU - Tabor, J.B. AU - Chilvers, M. AU - Dukelow, S. AU - Ho, C. AU - Campbell, C. AU - Sen, A. AU - Debert, C.T. AU - Sanati-Nezhad, A. TI - Nanoporous Carbon Immunosensor for Highly Accurate and Sensitive Clinical Detection of Glial Fibrillary Acidic Protein in Traumatic Brain Injury, Stroke, and Spinal Cord Injury JF - ACS BIOMATERIALS-SCIENCE & ENGINEERING J2 - ACS BIOMAT SCI ENG PY - 2023 SN - 2373-9878 DO - 10.1021/acsbiomaterials.3c00048 UR - https://m2.mtmt.hu/api/publication/33812917 ID - 33812917 N1 - BioMEMS and Bioinspired Microfluidic Laboratory, Department of Biomedical Engineering, University of Calgary, Calgary, AB T2N 1N4, Canada Biomedical Engineering Graduate Program, University of Calgary, Calgary, AB T2N 1N4, Canada Department of Mechanical and Manufacturing Engineering, Schulich School of Engineering, University of Calgary, Calgary, AB T2N 1N4, Canada Laboratory of Advanced Biotechnologies for Health Assessments (LAB-HA), Department of Electrical Engineering and Computer Science, Lassonde School of Engineering, York University, Toronto, M3J 1P3, Canada Pharmaceutical Production Research Facility, Schulich School of Engineering, University of Calgary, Alberta, T2N 1N4, Canada Department of Chemical and Petroleum Engineering, University of Calgary, Calgary, AB T2N 1N4, Canada Department of Clinical Neurosciences, Hotchkiss Brain Institute, Alberta Children Hospital Research Institute for Child and Maternal Health, University of Calgary, Calgary, AB T2N 1N4, Canada Department of Clinical Neurosciences, Division of Physical Medicine and Rehabilitation, Foothills Medical Centre, University of Calgary, Calgary, AB T2H 2T9, Canada Sport Injury Prevention Research Centre, Faculty of Kinesiology, University of Calgary, Calgary, AB T2N 1N4, Canada Export Date: 12 May 2023 Correspondence Address: Sanati-Nezhad, A.; BioMEMS and Bioinspired Microfluidic Laboratory, Canada; email: amir.sanatinezhad@ucalgary.ca Funding details: CMC Microsystems, CMC Funding details: Natural Sciences and Engineering Research Council of Canada, NSERC Funding details: Canada Research Chairs Funding details: Alberta Innovates, AI Funding text 1: The authors acknowledge the Natural Sciences and Engineering Research Council of Canada (NSERC), Canada Research Chair, Alberta Innovates AI Advance, Canadian Institutes of Health Research (CIHR), Alberta Innovates BioSolutions (AIBS), and CMC─Microsystems, Canada, for supporting this research. AB - Elevated glial fibrillary acidic protein (GFAP) in the blood serum is one of the promising bodily fluid markers for the diagnosis of central nervous system (CNS) injuries, including traumatic brain injury (TBI), stroke, and spinal cord injury (SCI). However, accurate and point-of-care (POC) quantification of GFAP in clinical blood samples has been challenging and yet to be clinically validated against gold-standard assays and outcome practices. This work engineered and characterized a novel nanoporous carbon screen-printed electrode with significantly increased surface area and conductivity, as well as preserved stability and anti-fouling properties. This nano-decorated electrode was immobilized with the target GFAP antibody to create an ultrasensitive GFAP immunosensor and quantify GFAP levels in spiked samples and the serum of CNS injury patients. The immunosensor presented a dynamic detection range of 100 fg/mL to 10 ng/mL, a limit of detection of 86.6 fg/mL, and a sensitivity of 20.3 Ω mL/pg mm2 for detecting GFAP in the serum. Its clinical utility was demonstrated by the consistent and selective quantification of GFAP comparable to the ultrasensitive single-molecule array technology in 107 serum samples collected from TBI, stroke, and SCI patients. Comparing the diagnostic and prognostic performance of the immunosensor with the existing clinical paradigms confirms the immunosensor’s accuracy as a potential complement to the existing imaging diagnostic modalities and presents a potential for rapid, accurate, cost-effective, and near real-time POC diagnosis and prognosis of CNS injuries. © 2023 American Chemical Society. LA - English DB - MTMT ER - TY - JOUR AU - Liu, J. AU - Zhang, G.-B. TI - Research progress on cerebrospinal fluid markers in traumatic brain injury JF - ZHONGGUO XIANDAI SHENJING JIBING ZAZHI / CHINESE JOURNAL OF CONTEMPORARY NEUROLOGY AND NEUROSURGERY J2 - CHIN J CONTEMP NEUROLNEUROSURG VL - 23 PY - 2023 IS - 10 SP - 884 EP - 888 PG - 5 SN - 1672-6731 DO - 10.3969/j.issn.1672-6731.2023.10.003 UR - https://m2.mtmt.hu/api/publication/34560068 ID - 34560068 N1 - Export Date: 6 February 2024 Correspondence Address: Zhang, G.-B.; Department of Traumatic Brain Injury, China; email: cntjzgb@hotmail.com LA - Chinese DB - MTMT ER - TY - JOUR AU - McBride, William R. AU - Eltman, Nicholas R. AU - Swanson, Randel L. TI - Blood-Based Biomarkers in Traumatic Brain Injury: A Narrative Review With Implications for the Legal System JF - CUREUS J2 - CUREUS VL - 15 PY - 2023 IS - 6 PG - 9 SN - 2168-8184 DO - 10.7759/cureus.40417 UR - https://m2.mtmt.hu/api/publication/34182001 ID - 34182001 AB - Traumatic brain injury (TBI) is an increasingly recognized diagnosis with significant, and often costly, associated consequences. Yet, despite their increased recognition, TBIs remain underdiagnosed. This issue is especially prominent in the context of mild TBI (mTBI), where there often exists little to no objective evidence of brain injury. In recent years, considerable effort has been made to better define and interpret known objective markers of TBI, as well as identify and explore new ones. An area of particular interest has focused on research related to blood-based biomarkers of TBI. Advancements in our understanding of TBI-related biomarkers can make it possible to characterize the severity of TBI with greater accuracy, improve our understanding of staging within both the injury process and the recovery process, and help us develop quantifiable metrics representative of reversal and recovery from a brain injury following trauma. Proteomic and non-proteomic blood-based biomarkers are being studied extensively and have shown promise for these purposes. Developments in this realm have significant implications not only for clinical care but also for legislation, as well as civil and criminal litigation. Despite their substantial potential, most of these biomarkers are not yet ready for use within the clinical setting, and therefore, are not appropriate for use within the legal or policy-making systems at this time. Given that existing standardization for the accurate and reliable use of TBI biomarkers is currently insufficient for use within either the clinical or legal realms, such data can be vulnerable to misuse and can even result in the abuse of the legal system for unwarranted gain. Courts will need to carefully evaluate the information presented in their role as gatekeepers of the admissibility of scientific evidence within the legal process. Ultimately, the development of biomarkers should lead to improved clinical care following TBI exposure, coherent and informed laws surrounding TBI, and more accurate and just results in litigation surrounding TBI-related sequelae. LA - English DB - MTMT ER - TY - JOUR AU - Nguyen, Andrew M. AU - Saini, Vishal AU - Hinson, H. E. TI - Blood-Based Biomarkers for Neuroprognostication in Acute Brain Injury JF - SEMINARS IN NEUROLOGY J2 - SEMIN NEUROL PY - 2023 PG - 10 SN - 0271-8235 DO - 10.1055/s-0043-1775764 UR - https://m2.mtmt.hu/api/publication/34256205 ID - 34256205 N1 - Export Date: 28 November 2023; CODEN: SEMNE AB - Acute brain injury causes loss of functionality in patients that often is devastating. Predicting the degree of functional loss and overall prognosis requires a multifaceted approach to help patients, and more so their families, make important decisions regarding plans and goals of care. A variety of blood-based markers have been studied as one aspect of this determination. In this review, we discuss CNS-derived and systemic markers that have been studied for neuroprognostication purposes. We discuss the foundation of each protein, the conditions in which it has been studied, and how the literature has used these markers for interpretation. We also discuss challenges to using each marker in each section as well. LA - English DB - MTMT ER - TY - JOUR AU - Olczak, Mieszko AU - Poniatowski, Lukasz A. AU - Siwinska, Agnieszka AU - Kwiatkowska, Magdalena TI - Post-mortem detection of neuronal and astroglial biochemical markers in serum and urine for diagnostics of traumatic brain injury JF - INTERNATIONAL JOURNAL OF LEGAL MEDICINE J2 - INT J LEGAL MED VL - 137 PY - 2023 IS - 5 SP - 1441 EP - 1452 PG - 12 SN - 0937-9827 DO - 10.1007/s00414-023-02990-7 UR - https://m2.mtmt.hu/api/publication/34248662 ID - 34248662 N1 - Funding Agency and Grant Number: Medical University of Warsaw [1MB/PM1/18]; European Union (EU) - the European Regional Development Fund (ERDF); European Union (EU) - the European Regional Development Fund (ERDF) Funding text: This study was supported by internal grant 1MB/PM1/18 conducted in the 2018-2019 years from the Medical University of Warsaw. The project was implemented with infrastructure financed by the European Union (EU) - the European Regional Development Fund (ERDF) within the "Infrastructure and Environment" operational program for 2007-2013 years. No additional external funding and support was received for this study. AB - Currently available epidemiological data shows that traumatic brain injury (TBI) represents one of the leading causes of death that is associated with medico-legal practice, including forensic autopsy, criminological investigation, and neuropathological examination. Attention focused on TBI research is needed to advance its diagnostics in ante- and post-mortem cases with regard to identification and validation of novel biomarkers. Recently, several markers of neuronal, astroglial, and axonal injury have been explored in various biofluids to assess the clinical origin, progression, severity, and prognosis of TBI. Despite clinical usefulness, understanding their diagnostic accuracy could also potentially help translate them either into forensic or medico-legal practice, or both. The aim of this study was to evaluate post-mortem pro-BDNF, NSE, UCHL1, GFAP, S100B, SPTAN1, NFL, MAPT, and MBP levels in serum and urine in TBI cases. The study was performed using cases (n = 40) of fatal head injury and control cases (n = 20) of sudden death. Serum and urine were collected within similar to 24 h after death and compared using ELISA test. In our study, we observed the elevated concentration levels of GFAP and MAPT in both serum and urine, elevated concentration levels of S100B and SPTAN1 in serum, and decreased concentration levels of pro-BDNF in serum compared to the control group. The obtained results anticipate the possible implementation of performed assays as an interesting tool for forensic and medico-legal investigations regarding TBI diagnosis where the head injury was not supposed to be the direct cause of death. LA - English DB - MTMT ER - TY - JOUR AU - Tomaiuolo, Rossella AU - Zibetti, Martina AU - Di Resta, Chiara AU - Banfi, Giuseppe TI - Challenges of the Effectiveness of Traumatic Brain Injuries Biomarkers in the Sports-Related Context JF - JOURNAL OF CLINICAL MEDICINE J2 - J CLIN MED VL - 12 PY - 2023 IS - 7 PG - 19 SN - 2077-0383 DO - 10.3390/jcm12072563 UR - https://m2.mtmt.hu/api/publication/33868395 ID - 33868395 N1 - Faculty of Medicine, Università Vita-Salute San Raffaele, Milan, 20132, Italy IRCCS Galeazzi-Sant’Ambrogio, Milan, 20157, Italy Cited By :1 Export Date: 1 February 2024 Correspondence Address: Di Resta, C.; Faculty of Medicine, Italy; email: diresta.chiara@hsr.it AB - Traumatic brain injury affects 69 million people every year. One of the main limitations in managing TBI patients is the lack of univocal diagnostic criteria, including the absence of standardized assessment methods and guidelines. Computerized axial tomography is the first-choice examination, despite the limited prevalence of positivity; moreover, its performance is undesirable due to the risk of radiological exposure, prolonged stay in emergency departments, inefficient use of resources, high cost, and complexity. Furthermore, immediacy and accuracy in diagnosis and management of TBIs are critically unmet medical needs. Especially in the context of sports-associated TBI, there is a strong need for prognostic indicators to help diagnose and identify at-risk subjects to avoid their returning to play while the brain is still highly vulnerable. Fluid biomarkers may emerge as new prognostic indicators to develop more accurate prediction models, improving risk stratification and clinical decision making. This review describes the current understanding of the cellular sources, temporal profile, and potential utility of leading and emerging blood-based protein biomarkers of TBI; its focus is on biomarkers that could improve the management of mild TBI cases and can be measured readily and directly in the field, as in the case of sports-related contexts. LA - English DB - MTMT ER - TY - JOUR AU - Wihersaari, Lauri AU - Reinikainen, Matti AU - Tiainen, Marjaana AU - Bendel, Stepani AU - Kaukonen, Kirsi-Maija AU - Vaahersalo, Jukka AU - Romppanen, Jarkko AU - Pettila, Ville B. AU - Skrifvars, Markus TI - Ubiquitin C-terminal hydrolase L1 after out-of-hospital cardiac arrest JF - ACTA ANAESTHESIOLOGICA SCANDINAVICA J2 - ACTA ANAESTH SCAND PY - 2023 PG - 8 SN - 0001-5172 DO - 10.1111/aas.14257 UR - https://m2.mtmt.hu/api/publication/33868145 ID - 33868145 N1 - Funding Agency and Grant Number: Academy of Finland; Finska Laekaresaellskapet; Kuopion Yliopistollinen Sairaala Funding text: Academy of Finland; Finska Laekaresaellskapet; Kuopion Yliopistollinen Sairaala AB - Background: We studied the prognostic ability of serum ubiquitin C-terminal hydrolase L1 (UCH-L1) after out-of-hospital cardiac arrest (OHCA), compared to that of neuron-specific enolase (NSE).Methods: In this post-hoc analysis of the FINNRESUSCI study, we measured serum concentrations of UCH-L1 in 249 OHCA patients treated in 21 Finnish intensive care units in 2010-2011. We evaluated the ability of UCH-L1 to predict unfavourable outcome at 12 months (defined as cerebral performance category 3-5) by assessing the area under the receiver operating characteristic curve (AUROC), in comparison with NSE.Results: The concentrations of UCH-L1 were higher in patients with unfavourable outcome than for those with favourable outcome: median concentration 10.8 ng/mL (interquartile range, 7.5-18.5 ng/mL) versus 7.8 ng/mL (5.9-11.8 ng/mL) at 24 h (p < .001), and 16.2 ng/mL (12.2-27.7 ng/mL) versus 11.5 ng/mL (9.0-17.2 ng/mL) (p < .001) at 48 h after OHCA. For UCH-L1 as a 12-month outcome predictor, the AUROC was 0.66 (95% confidence interval, 0.60-0.73) at 24 h and 0.66 (0.59-0.74) at 48 h. For NSE, the AUROC was 0.66 (0.59-0.73) at 24 h and 0.72 (0.65-0.80) at 48 h. The prognostic ability of UCH-L1 was not different from that of NSE at 24 h (p = .82) and at 48 h (p = .23).Conclusion: Concentrations of UCH-L1 in serum were higher in patients with unfavourable outcome than in those with favourable outcome. However, the ability of UCH-L1 to predict unfavourable outcome after OHCA was only moderate and not superior to that of NSE. LA - English DB - MTMT ER - TY - JOUR AU - Abdelhak, Ahmed AU - Foschi, Matteo AU - Abu-Rumeileh, Samir AU - Yue, John K. AU - D'Anna, Lucio AU - Huss, Andre AU - Oeckl, Patrick AU - Ludolph, Albert C. AU - Kuhle, Jens AU - Petzold, Axel AU - Manley, Geoffrey T. AU - Green, Ari J. AU - Otto, Markus AU - Tumani, Hayrettin TI - Blood GFAP as an emerging biomarker in brain and spinal cord disorders JF - NATURE REVIEWS NEUROLOGY J2 - NAT REV NEUROL VL - 18 PY - 2022 IS - 3 SP - 158 EP - 172 PG - 15 SN - 1759-4758 DO - 10.1038/s41582-021-00616-3 UR - https://m2.mtmt.hu/api/publication/32688987 ID - 32688987 N1 - Funding Agency and Grant Number: Michael J. Fox Foundation for Parkinson's Research [MJFF-010349]; Alzheimer Forschung Initiative e.V. [20059CB]; Swiss National Research Foundation [320030_189140/1]; US Department of Defense -TBI Endpoints Development Initiative [W81XWH-14-2-0176]; TRACK-TBI Precision Medicine [W81XWH-18-2-0042]; TRACK-TBI NETWORK [W81XWH-15-9-0001]; NIH-NINDS TRACK-TBI [U01NS086090]; NIH-NINDS -TRACK-TBI [U01NS086090]; Swiss National Science Foundation (SNF) [320030_189140] Funding Source: Swiss National Science Foundation (SNF) Funding text: A.A. received research grants from the German Multiple Sclerosis Society (DMSG). P. O. received research support from the Michael J. Fox Foundation for Parkinson ' s Research (grant ID MJFF-010349) and Alzheimer Forschung Initiative e.V. (20059CB). J.K. received speaker fees, research support, travel support and/or served on advisory boards of the Swiss MS Society, Swiss National Research Foundation (320030_189140/1), University of Basel, Progressive MS Alliance, Bayer, Biogen, Celgene, Merck, Novartis, Roche and Sanofi. G.T.M. reports funding from the US Department of Defense -TBI Endpoints Development Initiative (grant #W81XWH-14-2-0176), TRACK-TBI Precision Medicine (grant #W81XWH-18-2-0042), TRACK-TBI NETWORK (grant #W81XWH-15-9-0001), NIH-NINDS TRACK-TBI (grant #U01NS086090), National Football League (NFL) Scientific Advisory Board, with support from the NFL for the research efforts of TRACK-TBI NETWORK. In addition, the US Department of Energy supports G.T.M. for a precision medicine collaboration, Abbott Laboratories has provided funding for TRACK-TBI clinical studies, NeuroTrauma Sciences LLC has provided funding to support TRACK-TBI data curation efforts, One Mind has provided funding for TRACK-TBI patients stipends and support to clinical sites. J.K.Y. received funding from NIH-NINDS -TRACK-TBI (grant #U01NS086090). A.J.G. reports personal fees from Bionure, Mylan, Neurona and Viela Bio; other support from Pipeline Therapeutics; and grants and other support from Inception Sciences outside the submitted work. M. O. gave scientific advice to Axon, Biogen Idec, Fujirebio and Roche. H.T. reports funding for research projects, lectures and travel from Bayer, Biogen, Genzyme, Merck Serono, Novartis, Roche and Teva, and received research support from DMSG and the German Ministry for Education and Research (BMBF). No other disclosures are reported. AB - Blood-derived biomarkers for brain and spinal cord diseases are urgently needed. The introduction of highly sensitive immunoassays led to a rapid increase in the number of potential blood-derived biomarkers for diagnosis and monitoring of neurological disorders. In 2018, the FDA authorized a blood test for clinical use in the evaluation of mild traumatic brain injury (TBI). The test measures levels of the astrocytic intermediate filament glial fibrillary acidic protein (GFAP) and neuroaxonal marker ubiquitin carboxy-terminal hydrolase L1. In TBI, blood GFAP levels are correlated with clinical severity and extent of intracranial pathology. Evidence also indicates that blood GFAP levels hold the potential to reflect, and might enable prediction of, worsening of disability in individuals with progressive multiple sclerosis. A growing body of evidence suggests that blood GFAP levels can be used to detect even subtle injury to the CNS. Most importantly, the successful completion of the ongoing validation of point-of-care platforms for blood GFAP might ameliorate the decision algorithms for acute neurological diseases, such as TBI and stroke, with important economic implications. In this Review, we provide a systematic overview of the evidence regarding the utility of blood GFAP as a biomarker in neurological diseases. We propose a model for GFAP concentration dynamics in different conditions and discuss the limitations that hamper the widespread use of GFAP in the clinical setting. In our opinion, the clinical use of blood GFAP measurements has the potential to contribute to accelerated diagnosis and improved prognostication, and represents an important step forward in the era of precision medicine. In this Review, the authors provide an overview of the evidence regarding the use of blood levels of glial fibrillary acidic protein as a biomarker in a range of neurological diseases, including traumatic brain injury, stroke, multiple sclerosis and Alzheimer disease. LA - English DB - MTMT ER - TY - JOUR AU - Borumand, M.R. AU - Babaloii, F. AU - Mirmotahari, S.A. AU - Maghsoudi, A.S. AU - Torabi, R. AU - Mojtahedzadeh, M. AU - Norouzi, P. AU - Rad-Malekshahi, M. AU - Javar, H.A. AU - Hassani, S. TI - Recent trends and innovations in biosensors development for biomarkers towards monitoring traumatic brain injury JF - BIOSENSORS AND BIOELECTRONICS: X J2 - BIOSENS BIOELECTRON: X VL - 12 PY - 2022 SN - 2590-1370 DO - 10.1016/j.biosx.2022.100247 UR - https://m2.mtmt.hu/api/publication/34560080 ID - 34560080 N1 - Department of Pharmaceutical Biomaterials and Medical Biomaterial Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Laboratory of Bioanalysis, Institute of Biochemistry & Biophysics, Tehran University, Tehran, Iran Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Center of Excellence in Electrochemistry, School of Chemistry, College of Science, University of Tehran, Tehran, Iran Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran Cited By :1 Export Date: 6 February 2024 Correspondence Address: Hassani, S.; Toxicology and Diseases Group (TDG), Iran; email: Shokoufehasani@gmail.com Correspondence Address: Javar, H.A.; Department of Pharmaceutics, Iran; email: akbarijo@tums.ac.ir LA - English DB - MTMT ER - TY - JOUR AU - Dereli, Ayse Kurtulus AU - Secme, Mucahit AU - Acar, Kemalettin TI - Analysis of Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase L1 in Postmortem Serum and Cerebrospinal Fluid in Traumatic Cerebral Deaths JF - CLINICAL AND EXPERIMENTAL HEALTH SCIENCES J2 - CLIN EXP HEALTH SCI VL - 12 PY - 2022 IS - 1 SP - 242 EP - 248 PG - 7 SN - 2459-1459 DO - 10.33808/clinexphealthsci.943779 UR - https://m2.mtmt.hu/api/publication/32964976 ID - 32964976 N1 - Funding Agency and Grant Number: Scientific Research Coordination Unit of Pamukkale University [2018HZDP017] Funding text: This study was supported by Scientific Research Coordination Unit of Pamukkale University under the project number 2018HZDP017. AB - Objective: There is a growing body of research aimed at identifying biological markers that could indicate traumatic cerebral deaths such as traumatic brain damage in the postmortem period. In the event of astrocytic and neuronal injury, glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) are released into cerebrospinal fluid and blood. In the postmortem identification of traumatic brain injury, the present research explores the ability of GFAP and UCH-L1.Methods: Cerebrospinal fluid and blood samples were obtained from medicolegal autopsies, 17 cases with severe head trauma, 9 cases with the non-lethal head trauma group and 18 control cases. UCH-L1 and GFAP levels in postmortem cerebrospinal fluid and serum were determined from an enzyme-linked immunosorbent assay (ELISA).Results: GFAP level in cerebrospinal fluid and serum was 2.68 +/- 0.67 ng/ml and 0.79 +/- 0.92 ng/ml in the lethal head trauma group, 2.74 +/- 0.64 ng/ml and 1.05 +/- 0.68 ng/ml the non-lethal head trauma group and 2.49 +/- 0.55 ng/ml and 1.05 +/- 0.89 ng/ml in the control group, respectively. UCH-L1 level in cerebrospinal fluid and serum was 3.02 +/- 0.68 ng/ml and 2.69 +/- 0.77 ng/ml in the lethal head trauma group, 3.34 +/- 0.70 ng/ml and 2.59 +/- 0.65 ng/ml the non-lethal head trauma group and 3.28 +/- 0.33 ng/ml and 2.74 +/- 0.34 ng/ml in the control group, respectively. Elevated cerebrospinal fluid and serum UCH-L1 and GFAP levels were observed in all cases, although absence of statistically significant difference between the trauma and control groups (p>0.05).Conclusion: Further studies are needed to assess whether postmortem serum and CSF GFAP and UCH-L1 concentrations increase regardless of the cause of death. LA - English DB - MTMT ER - TY - JOUR AU - Ghaith, Hazem S. AU - Nawar, Asmaa Ahmed AU - Gabra, Mohamed Diaa AU - Abdelrahman, Mohamed Essam AU - Nafady, Mohamed H. AU - Bahbah, Eshak I AU - Ebada, Mahmoud Ahmed AU - Ashraf, Ghulam Md AU - Negida, Ahmed AU - Barreto, George E. TI - A Literature Review of Traumatic Brain Injury Biomarkers JF - MOLECULAR NEUROBIOLOGY J2 - MOL NEUROBIOL VL - 59 PY - 2022 IS - 7 SP - 4141 EP - 4158 PG - 18 SN - 0893-7648 DO - 10.1007/s12035-022-02822-6 UR - https://m2.mtmt.hu/api/publication/32965355 ID - 32965355 N1 - Export Date: 3 August 2022 CODEN: MONBE AB - Research into TBI biomarkers has accelerated rapidly in the past decade owing to the heterogeneous nature of TBI pathologies and management, which pose challenges to TBI evaluation, management, and prognosis. TBI biomarker proteins resulting from axonal, neuronal, or glial cell injuries are widely used and have been extensively studied. However, they might not pass the blood-brain barrier with sufficient amounts to be detected in peripheral blood specimens, and further might not be detectable in the cerebrospinal fluid owing to flow limitations triggered by the injury itself. Despite the advances in TBI research, there is an unmet clinical need to develop and identify novel TBI biomarkers that entirely correlate with TBI pathologies on the molecular level, including mild TBI, and further enable physicians to predict patient outcomes and allow researchers to test neuroprotective agents to limit the extents of injury. Although the extracellular vesicles have been identified and studied long ago, they have recently been revisited and repurposed as potential TBI biomarkers that overcome the many limitations of the traditional blood and CSF assays. Animal and human experiments demonstrated the accuracy of several types of exosomes and miRNAs in detecting mild, moderate, and severe TBI. In this paper, we provide a comprehensive review of the traditional TBI biomarkers that are helpful in clinical practice. Also, we highlight the emerging roles of exosomes and miRNA being the promising candidates under investigation of current research. LA - English DB - MTMT ER - TY - JOUR AU - Hamdan, Jessica L. AU - Rath, Meghan AU - Sayoc, Jacqueline AU - Park, Joon-Young TI - A brief descriptive outline of the rules of mixed martial arts and concussion in mixed martial arts JF - JOURNAL OF EXERCISE REHABILITATION J2 - J EXERC REHABIL VL - 18 PY - 2022 IS - 3 SP - 142 EP - 154 PG - 13 SN - 2288-176X DO - 10.12965/jer.2244146.073 UR - https://m2.mtmt.hu/api/publication/33179112 ID - 33179112 N1 - Funding Agency and Grant Number: National Institute of Neurological Disorders and Stroke at the National Institutes of Health [NIH R01NS102157] Funding text: This work was supported by funding from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health (NIH R01NS102157 to J.Y.P.). AB - Mixed martial arts (MMA), a combat sport consisting of wrestling, boxing, and martial arts, is a popular activity associated with danger and violence. Of concern are the repetitive head impacts, both subconcussive and concussive, sustained by MMA athletes. The rules of MMA encourage head strikes, but there was no formal concussion protocol in the Ultimate Fighting Championship (UFC) until 2021. Because the UFC was established less than 30 years, the long-term consequences of these repetitive concussive head blows are lacking. In this review, we focus on current literature sought to summarize the current knowledge of repetitive head impacts and concussions in MMA. The objectives were to outline (a) the rules of MMA; (b) the postconcussion protocol for UFC athletes; (c) current behavioral and biochemical diagnostic measures; (d) epidemiology and prevalence of concussion in MMA; (e) long term effects of subconcussive repetitive head impacts; (f) biomechanics of head impacts; and (g) considerations and research topics that warrant future research. LA - English DB - MTMT ER - TY - JOUR AU - Hicks, Celeste AU - Dhiman, Akshima AU - Barrymore, Chauntel AU - Goswami, Tarun TI - Traumatic Brain Injury Biomarkers, Simulations and Kinetics JF - BIOENGINEERING J2 - BIOENGINEERING-BASEL VL - 9 PY - 2022 IS - 11 PG - 49 SN - 2306-5354 DO - 10.3390/bioengineering9110612 UR - https://m2.mtmt.hu/api/publication/33341015 ID - 33341015 N1 - Biomedical, Industrial and Human Factors Engineering, Wright State University, 3640 Col. Glen Hwy, Dayton, OH 45435, United States Boonshoft School of Medicine, Wright State University, 3640 Col. Glen Hwy, Dayton, OH 45435, United States Cited By :6 Export Date: 1 February 2024 Correspondence Address: Goswami, T.; Biomedical, 3640 Col. Glen Hwy, United States; email: tarun.goswami@wright.edu AB - This paper reviews the predictive capabilities of blood-based biomarkers to quantify traumatic brain injury (TBI). Biomarkers for concussive conditions also known as mild, to moderate and severe TBI identified along with post-traumatic stress disorder (PTSD) and chronic traumatic encephalopathy (CTE) that occur due to repeated blows to the head during one's lifetime. Since the pathways of these biomarkers into the blood are not fully understood whether there is disruption in the blood-brain barrier (BBB) and the time it takes after injury for the expression of the biomarkers to be able to predict the injury effectively, there is a need to understand the protein biomarker structure and other physical properties. The injury events in terms of brain and mechanics are a result of external force with or without the shrapnel, in the wake of a wave result in local tissue damage. Thus, these mechanisms express specific biomarkers kinetics of which reaches half-life within a few hours after injury to few days. Therefore, there is a need to determine the concentration levels that follow injury. Even though current diagnostics linking biomarkers with TBI severity are not fully developed, there is a need to quantify protein structures and their viability after injury. This research was conducted to fully understand the structures of 12 biomarkers by performing molecular dynamics simulations involving atomic movement and energies of forming hydrogen bonds. Molecular dynamics software, NAMD and VMD were used to determine and compare the approximate thermodynamic stabilities of the biomarkers and their bonding energies. Five biomarkers used clinically were S100B, GFAP, UCHL1, NF-L and tau, the kinetics obtained from literature show that the concentration values abruptly change with time after injury. For a given protein length, associated number of hydrogen bonds and bond energy describe a lower bound region where proteins self-dissolve and do not have long enough half-life to be detected in the fluids. However, above this lower bound, involving higher number of bonds and energy, we hypothesize that biomarkers will be viable to disrupt the BBB and stay longer to be modeled for kinetics for diagnosis and therefore may help in the discoveries of new biomarkers. LA - English DB - MTMT ER - TY - JOUR AU - Kobeissy, Firas AU - Mallah, Khalil AU - Zibara, Kazem AU - Dakroub, Fatima AU - Dalloul, Zeinab AU - Nasser, Mohammad AU - Nasrallah, Leila AU - Mallah, Zahraa AU - El-Achkar, Ghewa A. AU - Ramadan, Naify AU - Mohamed, Wael AU - Mondello, Stefania AU - Darwish, Hala AU - Hamade, Eva AU - Habib, Aida TI - The effect of clopidogrel and aspirin on the severity of traumatic brain injury in a rat model JF - NEUROCHEMISTRY INTERNATIONAL J2 - NEUROCHEM INT VL - 154 PY - 2022 PG - 9 SN - 0197-0186 DO - 10.1016/j.neuint.2022.105301 UR - https://m2.mtmt.hu/api/publication/32946840 ID - 32946840 N1 - Export Date: 3 August 2022 CODEN: NEUID AB - Traumatic Brain Injury (TBI) is one of the leading causes of death and disability worldwide. Aspirin (ASA) and clopidogrel (CLOP) are antiplatelet agents that inhibit platelet aggregation. They are implicated in worsening the intracerebral haemorrhage (ICH) risk post-TBI. However, antiplatelet drugs may also exert a neuroprotective effect post-injury. We determined the impact of ASA and CLOP treatment, alone or in combination, on ICH and brain damage in an experimental rat TBI model. We assessed changes in platelet aggregation and measured serum thromboxane by enzyme immune assay. We also explored a panel of brain damage and apoptosis biomarkers by immunoblotting. Rats were treated with ASA and/or CLOP for 48 h prior to TBI and sacrificed 48 h post-injury. In rats treated with antiplatelet agents prior to TBI, platelet aggregation was completely inhibited, and serum thromboxane was significantly decreased, compared to the TBI group without treatment. TBI increases UCHL-1 and GFAP, but decreases hexokinase expression compared to the non-injured controls. All groups treated with antiplatelet drugs prior to TBI had decreased UCH-L1 and GFAP serum levels compared to the TBI untreated group. Furthermore, the ASA and CLOP single treatments increased the hexokinase serum levels. We confirmed that alpha II-spectrin cleavage increased post-TBI, with the highest cleavage detected in CLOP-treated rats. Aspirin and/or CLOP treatment prior to TBI is a double-edged sword that exerts a dual effect post-injury. On one hand, ASA and CLOP single treatments increase the post-TBI ICH risk, with a further detrimental effect from the ASA + CLOP treatment. On the other hand, ASA and/or CLOP treatments are neuroprotective and result in a favourable profile of TBI injury markers. The ICH risk and the neuroprotection benefits from antiplatelet therapy should be weighed against each other to ameliorate the management of TBI patients. LA - English DB - MTMT ER - TY - CHAP AU - Kornguth, S. AU - Neal, Rutledge J. TI - Comparing radiation and traumatic brain injuries: New insights T2 - Cellular, Molecular, Physiological, and Behavioral Aspects of Traumatic Brain Injury PB - Elsevier SN - 9780128230367 PY - 2022 SP - 243 EP - 255 PG - 13 DO - 10.1016/B978-0-12-823036-7.00039-6 UR - https://m2.mtmt.hu/api/publication/34560157 ID - 34560157 N1 - Department of Neurology, Dell Medical School and the College of Education, The University of Texas at Austin, Austin, TX, United States Department of Kinesiology and Health Education, Dell Medical School and the College of Education, The University of Texas at Austin, Austin, TX, United States Department of Psychology, University of Texas at Austin, Austin Radiological Associates, Austin, TX, United States Export Date: 6 February 2024 LA - English DB - MTMT ER - TY - JOUR AU - Lee, Jinhee AU - Kane, Bryant J. AU - Khanwalker, Mukund AU - Sode, Koji TI - Development of an electrochemical impedance spectroscopy based biosensor for detection of ubiquitin C-Terminal hydrolase L1 JF - BIOSENSORS & BIOELECTRONICS J2 - BIOSENS BIOELECTRON VL - 208 PY - 2022 PG - 6 SN - 0956-5663 DO - 10.1016/j.bios.2022.114232 UR - https://m2.mtmt.hu/api/publication/32964896 ID - 32964896 N1 - Export Date: 3 August 2022 CODEN: BBIOE AB - Year over year, the incidence of traumatic brain injury (TBI) in the population is dramatically increasing; thus, timely diagnosis is crucial for improving patient outcomes in the clinic. Ubiquitin C-terminal hydrolase L1 (UCHL1), a blood-based biomarker, has been approved by the FDA as a promising quantitative indicator of mild TBI that arises in blood serum shortly after injury. Current gold standard techniques for its quantitation are timeconsuming and require specific laboratory equipment. Hence, development of a hand-held device is an attractive alternative. In this study, we report a novel system for rapid, one-step electrochemical UCH-L1 detection. Electrodes were functionalized with anti-UCH-L1 antibody, which was used as a molecular recognition element for selective sensing of UCH-L1. Electrochemical impedance spectroscopy (EIS) was used as a transduction method to quantify its binding. When the electrode was incubated with different concentrations of UCH-L1, impedance signal increased against a concentration gradient with high logarithmic correlation. Upon singlefrequency analysis, a second calibration curve with greater signal to noise was obtained, which was used to distinguish physiologically relevant concentrations of UCH-L1. Notably, our system could detect UCH-L1 within 5 min, without a washing step nor bound/free separation, and had resolution across concentrations ranging from 1 pM to 1000 pM within an artificial serum sample. These attributes, together with the miniaturization potential afforded by an impedimetric sensing platform, make this platform an attractive candidate for scale-up as a device for rapid, on-site detection of TBI. These findings may aid in the future development of sensing systems for quantitative TBI detection. LA - English DB - MTMT ER - TY - JOUR AU - McBride, William R. AU - Conlan, Caroline E. AU - Barylski, Nicole A. AU - Warneryd, Amelie C. AU - Swanson, Randel L. TI - Blood Biomarkers in Brain Injury Medicine JF - CURRENT PHYSICAL MEDICINE AND REHABILITATION REPORTS J2 - CURR PHYS MED REHABIL REP VL - 10 PY - 2022 IS - 2 SP - 114 EP - 121 PG - 8 SN - 2167-4833 DO - 10.1007/s40141-022-00343-w UR - https://m2.mtmt.hu/api/publication/32964977 ID - 32964977 N1 - Export Date: 3 August 2022 AB - Purpose of Review This review seeks to explore blood-based biomarkers with the potential for clinical implementation. Recent Findings Emerging non-proteomic biomarkers hold promise for more accurate diagnostic and prognostic capabilities, especially in the subacute to chronic phase of TBI recovery. Furthermore, there is a growing understanding of the overlap between TBI-related and dementia-related blood biomarkers. Given the significant heterogeneity inherent in the clinical diagnosis of traumatic brain injury (TBI), there has been an exponential increase in TBI-related biomarker research over the past two decades. While TBI-related biomarker assessments include both cerebrospinal fluid analysis and advanced neuroimaging modalities, blood-based biomarkers hold the most promise to be non-invasive biomarkers widely available to Brain Injury Medicine clinicians in diverse practice settings. In this article, we review the most relevant blood biomarkers for the field of Brain Injury Medicine, including both proteomic and non-proteomic blood biomarkers, biomarkers of cerebral microvascular injury, and biomarkers that overlap between TBI and dementia. LA - English DB - MTMT ER - TY - JOUR AU - Pandey, Vishram AU - Shukla, Dhaval AU - Nirmal, Shubham AU - Devi, Bhagavatula Indira AU - Christopher, Rita TI - Biomarkers in Traumatic Brain Injuries: Narrative Review JF - INDIAN JOURNAL OF NEUROTRAUMA J2 - INDIAN JOURNAL OF NEUROTRAUMA VL - 2 PY - 2022 SN - 0973-0508 DO - 10.1055/s-0042-1759853 UR - https://m2.mtmt.hu/api/publication/33548839 ID - 33548839 N1 - Funding Agency and Grant Number: ICMR [ICMR/007/306/2018/01056] Funding text: This work is part of a project titled "Development of a serum biomarker panel for predicting outcome of traumatic brain injuries," Funded by ICMR. ICMR/007/306/2018/01056. LA - English DB - MTMT ER - TY - JOUR AU - Pareja, Jennifer C. Munoz AU - Li, Xue AU - Gandham, Nithya AU - Wang, Kevin K. TI - Biomarkers in Moderate to Severe Pediatric Traumatic Brain Injury: A Review of the Literature JF - PEDIATRIC NEUROLOGY J2 - PEDIATR NEUROL VL - 130 PY - 2022 SP - 60 EP - 68 PG - 9 SN - 0887-8994 DO - 10.1016/j.pediatrneurol.2022.03.002 UR - https://m2.mtmt.hu/api/publication/32965354 ID - 32965354 N1 - Export Date: 3 August 2022 CODEN: PNEUE AB - Background: Despite decades of research, outcomes in pediatric traumatic brain injury (pTBI) remain highly variable. Brain biofluid-specific biomarkers from pTBI patients may allow us to diagnose and prognosticate earlier and with a greater degree of accuracy than conventional methods. This manuscript reviews the evidence surrounding current brain-specific biomarkers in pTBI and assesses the temporal relationship between the natural history of the traumatic brain injury (TBI) and measured biomarker levels. Methods: A literature search was conducted in the Ovid, PubMed, MEDLINE, and Cochrane databases seeking relevant publications. The study selection and screening process were documented in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram. Extraction forms included developmental stages of patients, type and biofluid source of biomarkers, brain injury type, and other relevant data. Results: The search strategy identified 443 articles, of which 150 examining the biomarkers of our interest were included. The references retrieved were examined thoroughly and discussed at length with a pediatric neurocritical care intensivist specializing in pTBI and a Ph.D. scientist with a high degree of involvement in TBI biomarker research, authoring a vast amount of literature in this field. Conclusions: TBI biomarkers might serve as valuable tools in the diagnosis and prognosis of pTBI. However, while each biomarker has its advantages, they are not without limitations, and therefore, further research is critical in pTBI biomarkers.(c) 2022 Elsevier Inc. All rights reserved. LA - English DB - MTMT ER - TY - JOUR AU - Supraja, Patta AU - Tripathy, Suryasnata AU - Vanjari, Siva Rama Krishna AU - Singh, Shiv Govind TI - Label-free, ultrasensitive and rapid detection of FDA-approved TBI specific UCHL1 biomarker in plasma using MWCNT-PPY nanocomposite as bio-electrical transducer: A step closer to point-of-care diagnosis of TBI JF - BIOSENSORS & BIOELECTRONICS J2 - BIOSENS BIOELECTRON VL - 216 PY - 2022 PG - 12 SN - 0956-5663 DO - 10.1016/j.bios.2022.114631 UR - https://m2.mtmt.hu/api/publication/33172758 ID - 33172758 N1 - Funding Agency and Grant Number: Department of Science and Technology (Fund for Improvement of S & T infrastructure) the Government of India Funding text: The authors acknowledge the Department of Science and Technology (Fund for Improvement of S & T infrastructure) the Government of India for funding research. AB - Traumatic Brain Injury (TBI), a major cause of mortality and neurological disability affecting people of all ages worldwide, remains a diagnostic and therapeutic challenge to date. Rapid, ultra-sensitive, selective, and wide-range detection of TBI biomarkers in easily accessible body fluids is an unmet clinical need. Considering this, in this work, we report the design and development of a facile, label-free, highly stable and sensitive, chemi-impedance-based sensing platform for rapid and wide range detection of Ubiquitin-carboxy terminal hydrolase L1 (UCHL1: FDA-approved TBI specific plasma biomarker), using carboxylic functionalized MWCNTs embedded polypyrrole (PPY) nanocomposites (PPY/f-MWCNT). The said nanocomposites were synthesized using chemical oxidative polymerization method. Herein, the functionalized MWCNTs are used as conducting fillers so as to increase the polymer's dielectric constant according to the micro-capacitor model, thereby augmenting both DC electrical conductivity and AC dielectric property of the nanocomposite. The proposed immunosensing platform comprises of PPY/f-MWCNT modified interdigitated microelectrode (ID mu Es) array, on which anti-UCHL1-antibodies are immobilized using suitable covalent chemistry. The AC electrical characterization of the nanocomposite modified ID mu Es, with and without the antibodies, was performed through generic capacitance vs. frequency (C-F, 1 KHz-1 MHz) and capacitance vs. applied bias (C-V, 0.1 V-1 V) measurements, using an Agilent B1500A parametric analyzer. The binding event of UCHL1 peptides to anti-UCHL1-antibodies was transduced in terms of normalised changes in parallel capacitance, via the C-F analysis. Further, we have tested the detection efficiency of the said immunoassay against UCHL1 spiked human plasma samples in the concentration range 10 fg/mL-1 mu g/mL. The proposed sensing platform detected UCHL1 in spiked-plasma samples linearly in the range of 10 fg/mL-1 ng/mL with a sensitivity and LoD of 4.22 ((delta C/C-0)/ng.mL(-1))/cm(2) and 0.363 fg/mL, respectively. Further, it showed excellent stability (30 weeks), repeatability, reproducibility, selectivity and interference-resistance. The proposed approach is label-free, and if desired, can be used in conjunction with DC measurements, for biosensing applications. LA - English DB - MTMT ER - TY - JOUR AU - Al-Adli, N. AU - Akbik, O.S. AU - Rail, B. AU - Montgomery, E. AU - Caldwell, C. AU - Barrie, U. AU - Vira, S. AU - Al, Tamimi M. AU - Bagley, C.A. AU - Aoun, S.G. TI - The Clinical Use of Serum Biomarkers in Traumatic Brain Injury: A Systematic Review Stratified by Injury Severity JF - WORLD NEUROSURGERY J2 - WORLD NEUROSURG VL - 155 PY - 2021 SP - e418 EP - e438 SN - 1878-8750 DO - 10.1016/j.wneu.2021.08.073 UR - https://m2.mtmt.hu/api/publication/34776740 ID - 34776740 N1 - Department of Neurological Surgery, UT Southwestern Medical Center, Dallas, TX, United States Department of Orthopedic Surgery, UT Southwestern Medical Center, Dallas, TX, United States Export Date: 08 April 2024; Cited By: 7; Correspondence Address: N. Al-Adli; Department of Neurological Surgery, UT Southwestern Medical Center, Dallas, United States; email: Nadeem.Al-adli@utsouthwestern.edu LA - English DB - MTMT ER - TY - JOUR AU - Maleki, Nasim AU - Finkel, Alan AU - Cai, Guoshuai AU - Ross, Alexandra AU - Moore, R. Davis AU - Feng, Xuesheng AU - Androulakis, X. Michelle TI - Post-traumatic Headache and Mild Traumatic Brain Injury: Brain Networks and Connectivity JF - CURRENT PAIN AND HEADACHE REPORTS J2 - CURR PAIN HEADACHE R VL - 25 PY - 2021 IS - 3 PG - 11 SN - 1531-3433 DO - 10.1007/s11916-020-00935-y UR - https://m2.mtmt.hu/api/publication/33638752 ID - 33638752 N1 - Export Date: 11 January 2024 CODEN: CPHRG AB - Purpose of Review Post-traumatic headache (PTH) consequent to mild traumatic brain injury (mTBI) is a complex, multidimensional, chronic neurological disorder. The purpose of this review is to evaluate the current neuroimaging studies on mTBI and PTH with a specific focus on brain networks and connectivity patterns. Recent Findings We present findings on PTH incidence and prevalence, as well as the latest neuroimaging research findings on mTBI and PTH. Additionally, we propose a new strategy in studying PTH following mTBI. The diversity and heterogeneity of pathophysiological mechanisms underlying mild traumatic brain injury pose unique challenges on how we interpret neuroimaging findings in PTH. Evaluating alterations in the intrinsic brain network connectivity patterns using novel imaging and analytical techniques may provide additional insights into PTH disease state and therefore inform effective treatment strategies. LA - English DB - MTMT ER - TY - JOUR AU - Mowbray, Max AU - Banbury, Carl AU - Rickard, Jonathan J. S. AU - Davies, David J. AU - Oppenheimer, Pola Goldberg TI - Development and Characterization of a Probe Device toward Intracranial Spectroscopy of Traumatic Brain Injury JF - ACS BIOMATERIALS-SCIENCE & ENGINEERING J2 - ACS BIOMAT SCI ENG VL - 7 PY - 2021 IS - 3 SP - 1252 EP - 1262 PG - 11 SN - 2373-9878 DO - 10.1021/acsbiomaterials.0c01156 UR - https://m2.mtmt.hu/api/publication/32370651 ID - 32370651 N1 - Funding Agency and Grant Number: Wellcome Trust [174ISSFPP]; EPSRC [EP/L016346/1]; National Institute for Health Research (NIHR) [DTAARGCQ19497]; Royal Academy of Engineering Research Fellowship [RF1415/14/28] Funding text: We acknowledge funding from the Wellcome Trust (174ISSFPP). C.B. gratefully acknowledges funding from EPSRC (EP/L016346/1) and the National Institute for Health Research (NIHR) (DTAARGCQ19497). P.G.O. acknowledges the Royal Academy of Engineering (grant no. RF1415/14/28) Research Fellowship. We would like to thank R. Campbell and Wards Engineering Rugby for their consultation in the initial prototype production. AB - Traumatic brain injury is a leading cause of mortality worldwide, often affecting individuals at their most economically active yet no primary disease-modifying interventions exist for their treatment. Real-time direct spectroscopic examination of the brain tissue within the context of traumatic brain injury has the potential to improve the understanding of injury heterogeneity and subtypes, better target management strategies and organ penetrance of pharmacological agents, identify novel targets for intervention, and allow a clearer understanding of fundamental biochemistry evolution. Here, a novel device is designed and engineered, delivering Raman spectroscopy-based measurements from the brain through clinically established cranial access techniques. Device prototyping is undertaken within the constraints imposed by the acquisition and site dimensions (standard intracranial access holes, probe's dimensions), and an artificial skull anatomical model with cortical impact is developed. The device shows a good agreement with the data acquired via a standard commercial Raman, and the spectra measured are comparable in terms of quality and detectable bands to the established traumatic brain injury model. The developed proof-of-concept device demonstrates the feasibility for real-time optical brain spectroscopic interface while removing the noise of extracranial tissue and with further optimization and in vivo validation, such technology will be directly translatable for integration into currently available standards of neurological care. LA - English DB - MTMT ER - TY - JOUR AU - Ranadive, Niraja AU - Arora, Devinder AU - Nampoothiri, Madhavan AU - Mudgal, Jayesh TI - Sirtuins, a potential target in Traumatic Brain Injury and relevant experimental models JF - BRAIN RESEARCH BULLETIN J2 - BRAIN RES BULL VL - 171 PY - 2021 SP - 135 EP - 141 PG - 7 SN - 0361-9230 DO - 10.1016/j.brainresbull.2021.03.016 UR - https://m2.mtmt.hu/api/publication/32420328 ID - 32420328 N1 - Funding Agency and Grant Number: Manipal Academy of Higher Education, Karnataka, India; Dr TMA Pai Structured PhD programme Funding text: The work was supported by Manipal Academy of Higher Education, Karnataka, India with Intramural Funding (MCOPS/IMF/2019) to JM and Scholarship to NR under Dr TMA Pai Structured PhD programme. AB - Traumatic brain injury (TBI) can simply be defined as a violent external injury to the head causing brain dysfunction. The primary injury occurs immediately on impact whereas the secondary injury begins minutes to months after impact. TBI affects a vast majority of population worldwide yet, there isn?t any therapeutic intervention available. Sirtuins (SIRTs) are important regulator proteins found in humans. In several neurodegenerative diseases, SIRTs have proven its neuroprotective actions. Owing to the pathophysiological similarities in these diseases and TBI, SIRTs may serve as a potential target for therapeutic intervention in TBI. This review aims to describe the relevance of SIRTs as a potential pharmacological target in TBI. Also, the experimental animal model of TBI explored to understand the role of SIRTs in TBI have been discussed. LA - English DB - MTMT ER - TY - JOUR AU - Turner, Stephanie AU - Lazarus, Rachel AU - Marion, Donald AU - Main, Keith L. TI - Molecular and Diffusion Tensor Imaging Biomarkers of Traumatic Brain Injury: Principles for Investigation and Integration JF - JOURNAL OF NEUROTRAUMA J2 - J NEUROTRAUM VL - 38 PY - 2021 IS - 13 SP - 1762 EP - 1782 PG - 21 SN - 0897-7151 DO - 10.1089/neu.2020.7259 UR - https://m2.mtmt.hu/api/publication/32188327 ID - 32188327 N1 - Funding Agency and Grant Number: DHA Contracting Office (CO-NCR) [HT0014-19-C-0004, HT0014] Funding text: The views expressed in this manuscript are those of the authors and do not necessarily represent the official policy or position of the Defense Health Agency, Department of Defense, or any other U.S. government agency. This work was prepared under Contract HT0014-19-C-0004 with DHA Contracting Office (CO-NCR) HT0014 and, therefore, is defined as U.S. Government work under Title 17 U.S.C.x101. Per Title 17 U.S.C.x105, copyright protection is not available for any work of the U.S. Government. For more information, please contact dha.DVBICinfo@mail.mil. Defense and Veterans Brain Injury Center, 1335 East-West Highway, Silver Spring, MD 20910, United States General Dynamics Information Technology, Falls Church, VA, United States Export Date: 10 September 2021 CODEN: JNEUE Correspondence Address: Main, K.L.; Defense and Veterans Brain Injury Center, 1335 East-West Highway, United States; email: Keith.l.main3.ctr@mail.mil Defense and Veterans Brain Injury Center, 1335 East-West Highway, Silver Spring, MD 20910, United States General Dynamics Information Technology, Falls Church, VA, United States Export Date: 14 September 2021 CODEN: JNEUE Correspondence Address: Main, K.L.; Defense and Veterans Brain Injury Center, 1335 East-West Highway, United States; email: Keith.l.main3.ctr@mail.mil AB - The last 20 years have seen the advent of new technologies that enhance the diagnosis and prognosis of traumatic brain injury (TBI). There is recognition that TBI affects the brain beyond initial injury, in some cases inciting a progressive neuropathology that leads to chronic impairments. Medical researchers are now searching for biomarkers to detect and monitor this condition. Perhaps the most promising developments are in the biomolecular and neuroimaging domains. Molecular assays can identify proteins indicative of neuronal injury and/or degeneration. Diffusion imaging now allows sensitive evaluations of the brain's cellular microstructure. As the pace of discovery accelerates, it is important to survey the research landscape and identify promising avenues of investigation. In this review, we discuss the potential of molecular and diffusion tensor imaging (DTI) biomarkers in TBI research. Integration of these technologies could advance models of disease prognosis, ultimately improving care. To date, however, few studies have explored relationships between molecular and DTI variables in patients with TBI. Here, we provide a short primer on each technology, review the latest research, and discuss how these biomarkers may be incorporated in future studies. LA - English DB - MTMT ER - TY - JOUR AU - Wang, Kevin K. W. AU - Kobeissy, Firas H. AU - Shakkour, Zaynab AU - Tyndall, J. Adrian TI - Thorough overview of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein as tandem biomarkers recently cleared by US Food and Drug Administration for the evaluation of intracranial injuries among patients with traumatic brain injury JF - ACUTE MEDICINE & SURGERY J2 - ACUTE MEDICINE & SURGERY VL - 8 PY - 2021 IS - 1 PG - 16 SN - 2052-8817 DO - 10.1002/ams2.622 UR - https://m2.mtmt.hu/api/publication/32197390 ID - 32197390 N1 - Funding Agency and Grant Number: US Department of DefenseUnited States Department of Defense [W81XWH-14-2-0176, W81XWH19-2-0012, W81XWH-18-2-0042]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1U01 NS086090-01]; Department of Emergency Medicine, University of Florida Funding text: This work was partially supported by funds from the US Department of Defense (W81XWH-14-2-0176; W81XWH19-2-0012; W81XWH-18-2-0042 [to K.K.W.]), the National Institutes of Health (1U01 NS086090-01 [to K.K.W.]), and the Department of Emergency Medicine, University of Florida (to J.A.T., F.H.K., and K.K.W.). AB - Traumatic brain injury (TBI) is a major cause of mortality and morbidity affecting all ages. It remains to be a diagnostic and therapeutic challenge, in which, to date, there is no Food and Drug Administration-approved drug for treating patients suffering from TBI. The heterogeneity of the disease and the associated complex pathophysiology make it difficult to assess the level of the trauma and to predict the clinical outcome. Current injury severity assessment relies primarily on the Glasgow Coma Scale score or through neuroimaging, including magnetic resonance imaging and computed tomography scans. Nevertheless, such approaches have certain limitations when it comes to accuracy and cost efficiency, as well as exposing patients to unnecessary radiation. Consequently, extensive research work has been carried out to improve the diagnostic accuracy of TBI, especially in mild injuries, because they are often difficult to diagnose. The need for accurate and objective diagnostic measures led to the discovery of biomarkers significantly associated with TBI. Among the most well-characterized biomarkers are ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. The current review presents an overview regarding the structure and function of these distinctive protein biomarkers, along with their clinical significance that led to their approval by the US Food and Drug Administration to evaluate mild TBI in patients. LA - English DB - MTMT ER - TY - JOUR AU - Yeung, Claudia AU - Bhatia, Rahul AU - Bhattarai, Bikash AU - Sinha, Madhumita TI - Role of Salivary Biomarkers in Predicting Significant Traumatic Brain Injury An Exploratory Study JF - PEDIATRIC EMERGENCY CARE J2 - PEDIATR EMERG CARE VL - 37 PY - 2021 IS - 12 SP - E1373 EP - E1376 PG - 4 SN - 0749-5161 DO - 10.1097/PEC.0000000000002050 UR - https://m2.mtmt.hu/api/publication/32689315 ID - 32689315 N1 - Funding Agency and Grant Number: Maricopa Medical Foundation's House Staff Achievement Grant Funding text: This researchwas supported by the Maricopa Medical Foundation's House Staff Achievement Grant awarded to C.Y. AB - Objectives The highest rates of traumatic brain injury (TBI)-related morbidity and mortality occur in young children and adolescents. The objective of this study was to describe the levels of 3 biomarkers (S100B, glial fibrillary acidic protein, neuron-specific enolase) in saliva of children with TBI requiring inpatient admission at a pediatric trauma center and compare these levels in children without TBI. Methods A convenience sample of 24 children aged 0 to 18 years, presenting with acute isolated TBI, was enrolled prospectively. The non-TBI comparison groups consisted of patients with medical complaints and musculoskeletal injuries only. Salivary specimens were collected, and biomarkers were measured using quantitative enzyme-linked immunosorbent assay method. Demographic, clinical data, and brain imaging findings were obtained. Results Seventy-four children were enrolled. Twenty-four had TBI (mean age, 5.07 years; SD, 4.8 years); 14 subjects (58.3%) with TBI were found to have significant traumatic brain injury (SBI) on computed tomography scan. S100B levels were significantly higher in TBI group compared with those with musculoskeletal injury only (median, 113.2 pg/mL vs 18 pg/mL; P = 0.021). Area under the receiver operating characteristic curve for S100B in predicting SBI was 0.675; the optimum threshold for S100B to achieve the optimum sensitivity and specificity of SBI was at 86.9 pg/mL for SBI versus no injury group. Conclusions S100B levels in saliva were higher in children with TBI and may be predictive of SBI identified by presence of computed tomography abnormalities. Larger studies are needed to replicate our findings in using a noninvasive diagnostic measure for children with TBI and SBI. LA - English DB - MTMT ER - TY - JOUR AU - Anderson, Taylor N. AU - Hinson, Holly E. TI - Damaged: Elevated GFAP and UCH-L1 as the Black Flag of Brain Injury JF - RESUSCITATION J2 - RESUSCITATION VL - 154 PY - 2020 SP - 110 EP - 111 PG - 2 SN - 0300-9572 DO - 10.1016/j.resuscitation.2020.07.002 UR - https://m2.mtmt.hu/api/publication/31715237 ID - 31715237 N1 - Funding Agency and Grant Number: NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K23NS110828-01A1] Funding text: NINDS grant number 1K23NS110828-01A1. Cited By :1 Export Date: 14 September 2021 CODEN: RSUSB Correspondence Address: Hinson, H.E.; Oregon Health & Science University PortlandUnited States; email: hinson@ohsu.edu LA - English DB - MTMT ER - TY - JOUR AU - Crupi, Rosalia AU - Cordaro, Marika AU - Cuzzocrea, Salvatore AU - Impellizzeri, Daniela TI - Management of Traumatic Brain Injury: From Present to Future JF - ANTIOXIDANTS J2 - ANTIOXIDANTS-BASEL VL - 9 PY - 2020 IS - 4 PG - 17 SN - 2076-3921 DO - 10.3390/antiox9040297 UR - https://m2.mtmt.hu/api/publication/31446031 ID - 31446031 N1 - Cited By :17 Export Date: 21 October 2021 Correspondence Address: Cuzzocrea, S.; Department of Chemical, Viale F. Stagno D’Alcontres 31, Italy; email: salvator@unime.it AB - TBI (traumatic brain injury) is a major cause of death among youth in industrialized societies. Brain damage following traumatic injury is a result of direct and indirect mechanisms; indirect or secondary injury involves the initiation of an acute inflammatory response, including the breakdown of the blood-brain barrier (BBB), brain edema, infiltration of peripheral blood cells, and activation of resident immunocompetent cells, as well as the release of numerous immune mediators such as interleukins and chemotactic factors. TBI can cause changes in molecular signaling and cellular functions and structures, in addition to tissue damage, such as hemorrhage, diffuse axonal damages, and contusions. TBI typically disturbs brain functions such as executive actions, cognitive grade, attention, memory data processing, and language abilities. Animal models have been developed to reproduce the different features of human TBI, better understand its pathophysiology, and discover potential new treatments. For many years, the first approach to manage TBI has been treatment of the injured tissue with interventions designed to reduce the complex secondary-injury cascade. Several studies in the literature have stressed the importance of more closely examining injuries, including endothelial, microglia, astroglia, oligodendroglia, and precursor cells. Significant effort has been invested in developing neuroprotective agents. The aim of this work is to review TBI pathophysiology and existing and potential new therapeutic strategies in the management of inflammatory events and behavioral deficits associated with TBI. LA - English DB - MTMT ER - TY - JOUR AU - Czeiter, Endre AU - Amrein, Krisztina AU - Gravesteijn, Benjamin Y AU - Lecky, Fiona AU - Menon, David K AU - Mondello, Stefania AU - Newcombe, Virginia F J AU - Richter, Sophie AU - Steyerberg, Ewout W AU - Vyvere, Thijs Vande AU - Verheyden, Jan AU - Xu, Haiyan AU - Yang, Zhihui AU - Maas, Andrew I R AU - Wang, Kevin K W AU - Büki, András TI - Blood biomarkers on admission in acute traumatic brain injury : Relations to severity, CT findings and care path in the CENTER-TBI study JF - EBIOMEDICINE J2 - EBIOMEDICINE VL - 56 PY - 2020 PG - 11 SN - 2352-3964 DO - 10.1016/j.ebiom.2020.102785 UR - https://m2.mtmt.hu/api/publication/31328719 ID - 31328719 N1 - * Megosztott szerzőség AB - Serum biomarkers may inform and improve care in traumatic brain injury (TBI). We aimed to correlate serum biomarkers with clinical severity, care path and imaging abnormalities in TBI, and explore their incremental value over clinical characteristics in predicting computed tomographic (CT) abnormalities.We analyzed six serum biomarkers (S100B, NSE, GFAP, UCH-L1, NFL and t-tau) obtained <24 h post-injury from 2867 patients with any severity of TBI in the Collaborative European NeuroTrauma Effectiveness Research (CENTER-TBI) Core Study, a prospective, multicenter, cohort study. Univariable and multivariable logistic regression analyses were performed. Discrimination was assessed by the area under the receiver operating characteristic curve (AUC) with 95% confidence intervals.All biomarkers scaled with clinical severity and care path (ER only, ward admission, or ICU), and with presence of CT abnormalities. GFAP achieved the highest discrimination for predicting CT abnormalities (AUC 0•89 [95%CI: 0•87-0•90]), with a 99% likelihood of better discriminating CT-positive patients than clinical characteristics used in contemporary decision rules. In patients with mild TBI, GFAP also showed incremental diagnostic value: discrimination increased from 0•84 [95%CI: 0•83-0•86] to 0•89 [95%CI: 0•87-0•90] when GFAP was included. Results were consistent across strata, and injury severity. Combinations of biomarkers did not improve discrimination compared to GFAP alone.Currently available biomarkers reflect injury severity, and serum GFAP, measured within 24 h after injury, outperforms clinical characteristics in predicting CT abnormalities. Our results support the further development of serum GFAP assays towards implementation in clinical practice, for which robust clinical assay platforms are required.CENTER-TBI study was supported by the European Union 7th Framework program (EC grant 602150). LA - English DB - MTMT ER - TY - JOUR AU - Hayhurst, Christina J. AU - Patel, Mayur B. AU - McNeil, J. Brennan AU - Girard, Timothy D. AU - Brummel, Nathan E. AU - Thompson, Jennifer L. AU - Chandrasekhar, Rameela AU - Ware, Lorraine B. AU - Pandharipande, Pratik P. AU - Ely, E. Wesley AU - Hughes, Christopher G. TI - Association of neuronal repair biomarkers with delirium among survivors of critical illness JF - JOURNAL OF CRITICAL CARE J2 - J CRIT CARE VL - 56 PY - 2020 SP - 94 EP - 99 PG - 6 SN - 0883-9441 DO - 10.1016/j.jcrc.2019.12.010 UR - https://m2.mtmt.hu/api/publication/31459443 ID - 31459443 N1 - Funding Agency and Grant Number: National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TR000445]; National Institutes on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG027472, AG045085]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [TR000445, AG027472, HL111111, GM120484, AG034257, AG035117, AG040549, HL103836]; Vanderbilt Faculty Research Scholars Program; Doris Duke FoundationDoris Duke Charitable Foundation (DDCF); VA Clinical Science Research and Development Service; American Geriatrics Society Jahnigen Career Development Award; Veterans Affairs Tennessee Valley Geriatric Research, Education and Clinical Center Funding text: This project was supported by CTSA award TR000445 from the National Center for Advancing Translational Sciences and by the National Institutes on Aging (AG027472, AG045085). In addition, Dr. Patel received support from the National Institutes of Health (HL111111, GM120484) and the Vanderbilt Faculty Research Scholars Program, Dr. Girard received support from the National Institutes of Health (AG034257, AG035117), Dr. Brummel received support from the National Institutes of Health (AG040549) and the Doris Duke Foundation, Dr. Ware received support from the National Institutes of Health (HL103836), Dr. Pandharipande received support from the National Institutes of Health (AG027472, HL111111, GM120484), Dr. Ely received support fromthe VA Clinical Science Research and Development Service and the National Institutes of Health (AG027472, AG035117, HL111111, GM120484), and Dr. Hughes received support from American Geriatrics Society Jahnigen Career Development Award and the National Institutes of Health (HL111111, AG045085, GM120484). Drs. Ely and Girard also received support from the Veterans Affairs Tennessee Valley Geriatric Research, Education and Clinical Center. We used REDCap, a secure online database, supported in part by the National Institutes of Health TR000445. AB - Purpose: Delirium is prevalent but with unclear pathogenesis. Neuronal injury repair pathways may be protective. We hypothesized that higher concentrations of neuronal repair biomarkers would be associated with decreased delirium in critically ill patients.Materials and methods: We performed a nested study of hospital survivors within a prospective cohort that enrolled patients within 72 h of respiratory failure or shock. We measured plasma concentrations of ubiquitin carboxyl-terminal-esterase-L1 (UCHLI ) and brain-derived neurotrophic factor (BDNF) from blood collected at enrollment. Delirium was assessed twice daily using the CAM-ICU. Multivariable regression was used to examine the associations between biomarkers and delirium prevalence/duration, adjusting for covariates and interactions with age and IL-6 plasma concentration.Results: We included 427 patients with a median age of 59 years (IQR 48-69) and APACHE II score of 25 (IQR 19-30). Higher plasma concentration of UCHLI on admission was independently associated with lower prevalence of delirium (p = .04) but not associated with duration of delirium (p = .06). BDNF plasma concentration was not associated with prevalence (p = .26) or duration of delirium (p = .36).Conclusions: During critical illness, higher UCHLI plasma concentration is associated with lower prevalence of delirium; BDNF plasma concentration is not associated with delirium. (C) 2019 Elsevier Inc. All rights reserved. LA - English DB - MTMT ER - TY - JOUR AU - Lewis, Jean M. AU - Dhawan, Sanjay AU - Obirieze, Augustine C. AU - Sarno, Benjamin AU - Akers, Johnny AU - Heller, Michael J. AU - Chen, Clark C. TI - Plasma Biomarker for Post-concussive Syndrome: A Pilot Study Using an Alternating Current Electro-Kinetic Platform JF - FRONTIERS IN NEUROLOGY J2 - FRONT NEUR VL - 11 PY - 2020 PG - 10 SN - 1664-2295 DO - 10.3389/fneur.2020.00685 UR - https://m2.mtmt.hu/api/publication/31459442 ID - 31459442 N1 - Funding Agency and Grant Number: DOD grant [W81XWH-14-20192]; National Science Foundation (NSF) Graduate Research Fellowship Program (GRFP) award [DGE-1650112] Funding text: This work was supported by DOD grant #W81XWH-14-20192 to MH and CC. Fellowship support was provided to AO by a National Science Foundation (NSF) Graduate Research Fellowship Program (GRFP) award under Grant #DGE-1650112. AB - Background:Technology platforms that afford biomarker discovery in patients suffering from traumatic brain injury (TBI) remain an unmet medical need. Here, we describe an observational pilot study to explore the utility of an alternating current electrokinetic (ACE) microchip device in this context. Methods:Blood samples were collected from participating subjects with and without minor TBI. Plasma levels of glial fibrillary acidic protein (GFAP), Tau, ubiquitin C-terminal hydrolase L1 (UCH-L1), and cell-free DNA (cfDNA) were determined in subjects with and without minor TBI using ACE microchip device followed by on-chip immunofluorescent analysis. Post-concussive symptoms were assessed using the Rivermead Post Concussion Symptoms Questionnaire (RPCSQ) at one-month follow-up. Results:Highest levels of GFAP, UCH-L1, and Tau were seen in two minor TBI subjects with abnormality on head computed tomography (CT). In patients without abnormal head CT, Tau and GFAP levels discriminated between plasma from minor-TBI and non-TBI patients, with sensitivity and specificity of 64-72 and 50%, respectively. Plasma GFAP, UCH-L1, and Tau strongly correlated with the cumulative RPCSQ score. Plasma UCH-L1 and GFAP exhibited highest correlation to sensitivity to noise and light (r= 0.96 and 0.91, respectively,p< 0.001). Plasma UCH-L1 and Tau showed highest correlation with headache (r= 0.74 and 0.78, respectively,p< 0.001), sleep disturbance (r= 0.69 and 0.84, respectively,p< 0.001), and cognitive symptoms, including forgetfulness (r= 0.76 and 0.74, respectively,p< 0.001), poor concentration (r= 0.68 and 0.76, respectively,p< 0.001), and time required for information processing (r= 0.77 and 0.81, respectively,p< 0.001). cfDNA exhibited a strong correlation with depression (r= 0.79,p< 0.01) and dizziness (r= 0.69,p< 0.01). While cfDNA demonstrated positive correlation with dizziness and depression (r= 0.69 and 0.79, respectively,p< 0.001), no significant correlation was observed between cumulative RPCSQ and cfDNA (r= 0.07,p= 0.81). Conclusion:We provide proof-of-principle results supporting the utility of ACE microchip for plasma biomarker analysis in patients with minor TBI. LA - English DB - MTMT ER - TY - JOUR AU - Selvakumar, Govindhasamy Pushpavathi AU - Ahmed, Mohammad Ejaz AU - Iyer, Shankar S. AU - Thangavel, Ramasamy AU - Kempuraj, Duraisamy AU - Raikwar, Sudhanshu P. AU - Bazley, Kieran AU - Wu, Kristopher AU - Khan, Asher AU - Kukulka, Klaudia AU - Bussinger, Bret AU - Zaheer, Smita AU - Burton, Casey AU - James, Donald AU - Zaheer, Asgar TI - Absence of Glia Maturation Factor Protects from Axonal Injury and Motor Behavioral Impairments after Traumatic Brain Injury JF - EXPERIMENTAL NEUROBIOLOGY J2 - EXP NEUROBIOL (KOREA) VL - 29 PY - 2020 IS - 3 SP - 230 EP - 248 PG - 19 SN - 1226-2560 DO - 10.5607/en20017 UR - https://m2.mtmt.hu/api/publication/31459441 ID - 31459441 N1 - Funding Agency and Grant Number: Leonard Wood Institute; U.S. Army Research LaboratoryUnited States Department of DefenseUS Army Research Laboratory (ARL) [W911NF-14-2-0034]; VA Research Career Scientist Award Funding text: Research was sponsored by the Leonard Wood Institute in cooperation with the U.S. Army Research Laboratory and was accomplished under Cooperative Agreement Number W911NF-14-2-0034. The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the Leonard Wood Institute, the Army Research Laboratory or the U.S. Government. The U.S. Government is authorized to reproduce and distribute reprints for Government purposes notwithstanding any copyright notation heron. The authors express their gratitude for the Acute Effects of Neurotrauma Consortium in assisting and coordinating the conduct of this project at Fort Leonard Wood. Dr Zaheer (AZ) is the recipient of the VA Research Career Scientist Award. Export Date: 7 December 2020 Harry S. Truman Memorial Veterans Hospital, Columbia, MO 65211, United States Department of Neurology Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO 65211, United States Phelps Health, Rolla, MO 65401, United States Cited By :3 Export Date: 14 September 2021 Correspondence Address: Zaheer, A.; Harry S. Truman Memorial Veterans HospitalUnited States; email: zaheera@health.missouri.edu AB - Traumatic brain injury (TBI) causes disability and death, accelerating the progression towards Alzheimer's disease and Parkinson's disease (PD). TBI causes serious motor and cognitive impairments. as seen in PD that arise during the period of the initial insult However, this has been understudied relative to TBI induced neuroinflammation, motor and cognitive decline that progress towards PD. Neuronal ubiquitin-C-terminal hydrolase-L1 (UCHL1) is a thiol protease that breaks down ubiquitinated proteins and its level represents the severity of TBI. Previously, vie demonstrated the molecular action of glia maturation factor (GMF); a proinflammatory protein in mediating neuroinflanunation and neuronal loss. Here. we show that the weight drop method induced TBI neuropathology using behavioral tests, western blotting, and immunofluorescence techniques on sections from wild type (WT) and GMF-deficient (GMF-KO) mice. Results reveal a significant improvement in substantia nigral tyrosine hydroxyiase and dopamine transporter expression with motor behavioral performance in GMF-KO mice following TBI. In addition, a significant reduction in neuroinflanunation was manifested, as shown by activation of nuclear factor-kB, reduced levels of inducible nitric oxide synthase, and cyclooxygenase-2 expressions. Likewise, neurotrophins including brain-derived neurotrophic factor and glial-derived neurotrophic factor were significantly improved in GMF-KO mice than WT 72 h post-TBI. Consistently we found that TBI enhances GFAP and UCHL-1 expression and reduces the number of dopaminergic TH-positive neurons in WT compared to GMF-KO mice 72 h post-TBI. Interestingly, we observed a reduction of TH-positive tanycytes in the median eminence of WT than GMF-KO mice. Overall, we found that absence of GMF significantly reversed these neuropathological events and improved behavioral outcome. This study provides evidence that PD-associated pathology progression can be initiated upon induction of TBI. LA - English DB - MTMT ER - TY - JOUR AU - Slavoaca, Dana AU - Muresanu, Dafin AU - Birle, Codruta AU - Rosu, Olivia Verisezan AU - Chirila, Ioana AU - Dobra, Iulia AU - Jemna, Nicoleta AU - Strilciuc, Stefan AU - Vos, Pieter TI - Biomarkers in traumatic brain injury: new concepts JF - NEUROLOGICAL SCIENCES J2 - NEUROL SCI VL - 41 PY - 2020 IS - 8 SP - 2033 EP - 2044 PG - 12 SN - 1590-1874 DO - 10.1007/s10072-019-04238-y UR - https://m2.mtmt.hu/api/publication/31308173 ID - 31308173 N1 - Cited By :2 Export Date: 19 February 2021 CODEN: NESCC Department of Neurosciences, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, Cluj-Napoca, 400486, Romania Neurology Clinic, Cluj Emergency County Hospital, Cluj-Napoca, Romania Department of Neurology, Slingeland Hospital, Doetinchem, Netherlands Cited By :6 Export Date: 13 September 2021 CODEN: NESCC Correspondence Address: Muresanu, D.; RoNeuro Institute for Neurological Research and Diagnostic, No. 37 Mircea Eliade Street, Romania; email: dafinm@ssnn.ro Export Date: 14 September 2021 CODEN: NESCC LA - English DB - MTMT ER - TY - JOUR AU - Tylicka, Marzena AU - Matuszczak, Ewa AU - Hermanowicz, Adam AU - Debek, Wojciech AU - Karpinska, Maria AU - Kaminska, Joanna AU - Koper-Lenkiewicz, Olga Martyna TI - BDNF and IL-8, But Not UCHL-1 and IL-11, Are Markers of Brain Injury in Children Caused by Mild Head Trauma JF - BRAIN SCIENCES J2 - BRAIN SCI VL - 10 PY - 2020 IS - 10 PG - 10 SN - 2076-3425 DO - 10.3390/brainsci10100665 UR - https://m2.mtmt.hu/api/publication/31714993 ID - 31714993 N1 - Department of Biophysics, Medical University of Białystok, Mickiewicza 2a, Białystok, 15-089, Poland Department of Pediatric Surgery and Urology, Medical University of Białystok, Waszyngtona 17, Białystok, 15-274, Poland Department of Clinical Laboratory Diagnostics, Medical University of Białystok, Waszyngtona 15A, Białystok, 15-269, Poland Export Date: 21 October 2021 Correspondence Address: Tylicka, M.; Department of Biophysics, Mickiewicza 2a, Poland; email: marzena.tylicka@umb.edu.pl Correspondence Address: Koper-Lenkiewicz, O.M.; Department of Clinical Laboratory Diagnostics, Waszyngtona 15A, Poland; email: o.koper@wp.pl AB - The aim of the study was to check whether the plasma levels of brain-derived neurotrophic factor (BDNF), interleukin-8 (IL-8), interleukin-11 (IL-11) and ubiquitin C-terminal hydrolase L1 (UCHL-1) change in children with mild head trauma (N = 29) compared to controls (N = 13). Protein concentration in children with mild head trauma (12 children with mild concussion without loss of consciousness and 17 children with severe concussion and loss of consciousness) and the control group were measured by means of the Enzyme-Linked Immunosorbent Assay (ELISA) method. IL-8 and BDNF concentration was statistically higher in the group of children with mild head trauma (9.89 pg/mL and 2798.00 pg/mL, respectively) compared to the control group (7.52 pg/mL and 1163.20 pg/mL, respectively). BDNF concentration was significantly higher in children with severe concussion and loss of consciousness (3826.00 pg/mL) than in the control group. None of the tested proteins differed significantly between children with mild concussion without loss of consciousness and children with severe concussion and loss of consciousness. BDNF and IL-8 may be sensitive markers of brain response to mild head trauma in children. The lack of statistical differences for BDNF and IL-8 between children with mild or severe concussion could indicate that their elevated levels may not result from significant structural brain damage but rather reflect a functional disturbance. LA - English DB - MTMT ER - TY - JOUR AU - Agoston, Denes V. AU - Kamnaksh, Alaa TI - Protein biomarkers of epileptogenicity after traumatic brain injury JF - NEUROBIOLOGY OF DISEASE J2 - NEUROBIOL DIS VL - 123 PY - 2019 SP - 59 EP - 68 PG - 10 SN - 0969-9961 DO - 10.1016/j.nbd.2018.07.017 UR - https://m2.mtmt.hu/api/publication/30487576 ID - 30487576 N1 - Export Date: 8 May 2019 CODEN: NUDIE Correspondence Address: Agoston, D.V.; Department of Anatomy, Physiology and Genetics, Uniformed Services University, 4301 Jones Bridge Rd, United States; email: denes.agoston@usuhs.edu Export Date: 13 May 2019 CODEN: NUDIE Correspondence Address: Agoston, D.V.; Department of Anatomy, Physiology and Genetics, Uniformed Services University, 4301 Jones Bridge Rd, United States; email: denes.agoston@usuhs.edu Funding Agency and Grant Number: NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U54 NS100064] Export Date: 19 August 2020 CODEN: NUDIE Cited By :3 Export Date: 10 March 2021 CODEN: NUDIE Correspondence Address: Agoston, D.V.; Department of Anatomy, 4301 Jones Bridge Rd, United States; email: denes.agoston@usuhs.edu Funding Agency and Grant Number: NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U54 NS100064] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U54NS100064] Funding Source: NIH RePORTER Cited By :6 Export Date: 13 September 2021 CODEN: NUDIE Correspondence Address: Agoston, D.V.; Department of Anatomy, 4301 Jones Bridge Rd, United States; email: denes.agoston@usuhs.edu Export Date: 14 September 2021 CODEN: NUDIE AB - Traumatic brain injury (TBI) is a major risk factor for acquired epilepsy. Post-traumatic epilepsy (PTE) develops over time in up to 50% of patients with severe TBI. PTE is mostly unresponsive to traditional anti-seizure treatments suggesting distinct, injury-induced pathomechanisms in the development of this condition. Moderate and severe TBIs cause significant tissue damage, bleeding, neuron and glia death, as well as axonal, vascular, and metabolic abnormalities. These changes trigger a complex biological response aimed at curtailing the physical damage and restoring homeostasis and functionality. Although a positive correlation exists between the type and severity of TBI and PTE, there is only an incomplete understanding of the time-dependent sequelae of TBI pathobiologies and their role in epileptogenesis. Determining the temporal profile of protein biomarkers in the blood (serum or plasma) and cerebrospinal fluid (CSF) can help to identify pathobiologies underlying the development of PTE, high-risk individuals, and disease modifying therapies. Here we review the pathobiological sequelae of TBI in the context of blood- and CSF-based protein biomarkers, their potential role in epileptogenesis, and discuss future directions aimed at improving the diagnosis and treatment of PTE. LA - English DB - MTMT ER - TY - JOUR AU - Chmielewska, Natalia AU - Maciejak, Piotr AU - Turzynska, Danuta AU - Sobolewska, Alicja AU - Wislowska-Stanek, Aleksandra AU - Kolosowska, Karolina AU - Plaznik, Adam AU - Szyndler, Janusz TI - The role of UCH-L1, MMP-9, and GFAP as peripheral markers of different susceptibility to seizure development in a preclinical model of epilepsy JF - JOURNAL OF NEUROIMMUNOLOGY J2 - J NEUROIMMUNOL VL - 332 PY - 2019 SP - 57 EP - 63 PG - 7 SN - 0165-5728 DO - 10.1016/j.jneuroim.2019.03.018 UR - https://m2.mtmt.hu/api/publication/30726465 ID - 30726465 N1 - Funding Agency and Grant Number: National Science Centre, PolandNational Science Centre, Poland [2014/13/B/NZ7/02277]; European Union - The European Regional Development Fund Funding text: This study was supported by Grant No. 2014/13/B/NZ7/02277 from the National Science Centre, Poland. Project implemented with CePT infrastructure financed by the European Union - The European Regional Development Fund within the operational program "Innovative economy" for 2007-2013. AB - In our study, we assessed the potency of the brain-derived proteins ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), matrix metalloproteinase 9 (MMP-9), glial fibrillary acidic protein (GFAP) and the immune activation indicators interleukin 1 beta (IL-1 beta) and interleukin 6 (IL-6) as peripheral biomarkers of different susceptibilities to kindling in a preclinical model. We observed increased plasma UCH-L1 levels in kindled vs. control animals. Furthermore, MMP-9 and IL-1 beta concentrations were the lowest in rats resistant to kindling. In summary, UCH-L1 is an indicator of neuronal loss and BBB disruption after seizure. MMP-9 and IL-1 beta may indicate resistance to kindling. UCH-L1, MMP-9 and IL-1 beta may have utility as peripheral biomarkers with translational potency in the clinic. LA - English DB - MTMT ER - TY - JOUR AU - Khetani, Sultan AU - Kollath, Vinayaraj Ozhukil AU - Eastick, Erin AU - Debert, Chantel AU - Sen, Arindom AU - Karan, Kunal AU - Sanati-Nezhad, Amir TI - Single-step functionalization of poly-catecholamine nanofilms for ultra-sensitive immunosensing of ubiquitin carboxyl terminal hydrolase-L1 (UCHL-1) in spinal cord injury JF - BIOSENSORS & BIOELECTRONICS J2 - BIOSENS BIOELECTRON VL - 145 PY - 2019 PG - 9 SN - 0956-5663 DO - 10.1016/j.bios.2019.111715 UR - https://m2.mtmt.hu/api/publication/31568696 ID - 31568696 N1 - Funding Agency and Grant Number: Natural Sciences and Engineering Research of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); Canada Research ChairNatural Resources CanadaCanadian Forest ServiceCanada Research Chairs; Alberta Prion Research Institute (APRI); Alberta Innovates BioSolutions (AIBS); CMC - Microsystems, Canada Funding text: The authors acknowledge Natural Sciences and Engineering Research of Canada (NSERC); Canada Research Chair; Alberta Prion Research Institute (APRI); Alberta Innovates BioSolutions (AIBS); and CMC - Microsystems, Canada for supporting this research. AB - Rapid, selective, and ultra-sensitive detection of brain and spinal cord injury markers in bodily fluids is an unmet clinical need. In this work, Polycatecholamine as a rich source of amine moieties was used for single-step fabrication of ultrasensitive immunosensors for the detection of Ubiquitin carboxyl-terminal hydrolase (UCHL-1) biomarker of brain and spinal cord injuries and address the clinical need. The surface of graphene electrodes was modified by electropolymerizing aqueous solution of dopamine (DA) and norepinephrine (NE) monomers for generating polycatecholamines nanofilms on the surface of graphene screen printed electrodes (GSPE) in a single functionalization step. Amine moieties of the polymer allowed immobilization of UCHL-1 antibody on the electrode. The single-step modification of GSPE offered a simple, ultrasensitive, and stable production of immunosensors for the detection of UCHL-1. The operational range of the UCHL-1 immunosensor developed with Polynorepinephrine pNE-modified is 0.1 pg mL(-1) - 10(5) pg mL(-1) (LOD: 1.91 pg mL(-1)), and 1 pg mL(-1) - 10(5) pg mL(-1) (LOD: 0.70 pg mL(-1)) with Polydopamine (pDA) modification, satisfying the clinical range. Both pNE and pDA modified immunosensors, detected UCHL-1 spiked in phosphate buffer saline, artificial cerebrospinal fluid, and serum. Along with the sensitive detections, selective performances were recorded in the above matrices in the presence of interfering neurotransmitters GABA and Glutamate as well as glial fibrillary acidic protein (GFAP). Upon testing clinical samples of spinal cord injury patients and healthy controls, both pNE and pDA immunosensors, delivered a comparable response for UCHL-1, thereby, making immunosensors useful for clinical settings. LA - English DB - MTMT ER - TY - JOUR AU - Korley, Frederick K AU - Yue, John K AU - Wilson, David H AU - Hrusovsky, Kevin AU - Diaz-Arrastia, Ramon AU - Ferguson, Adam R AU - Yuh, Esther L AU - Mukherjee, Pratik AU - Wang, Kevin K W AU - Valadka, Alex B AU - Puccio, Ava M AU - Okonkwo, David O AU - Manley, Geoffrey T TI - Performance Evaluation of a Multiplex Assay for Simultaneous Detection of Four Clinically Relevant Traumatic Brain Injury Biomarkers JF - JOURNAL OF NEUROTRAUMA J2 - J NEUROTRAUM VL - 36 PY - 2019 IS - 1 SP - 182 EP - 187 PG - 6 SN - 0897-7151 DO - 10.1089/neu.2017.5623 UR - https://m2.mtmt.hu/api/publication/27598132 ID - 27598132 N1 - Department of Emergency Medicine, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109, United States Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, United States Quanterix Corporation, Lexington, MA, United States Department of Neurology, University of Pennsylvania, Traumatic Brain Injury Clinical Research Center, Penn Presbyterian Medical Center, Philadelphia, PA, United States Department of Radiology, University of California, San Francisco, San Francisco, CA, United States Center for Neuroproteomics and Biomarkers Research, Department of Psychiatry, McKnight Brain Institute, University of Florida, Gainesville, FL, United States Department of Neurological Surgery, Virginia Commonwealth University, Richmond, VA, United States Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States Cited By :29 Export Date: 22 October 2021 CODEN: JNEUE Correspondence Address: Korley, F.K.; Department of Emergency Medicine, 1500 East Medical Center Drive, United States; email: korley@med.umich.edu LA - English DB - MTMT ER - TY - JOUR AU - Lan, Jiaming AU - Wu, Linfeng AU - Tan, Xingqin AU - Xiang, Li AU - Guo, Chunbao TI - Application of the cerebral edema monitor on cardiopulmonary bypass in infants JF - BRAIN INJURY J2 - BRAIN INJURY VL - 33 PY - 2019 IS - 10 SP - 1379 EP - 1384 PG - 6 SN - 0269-9052 DO - 10.1080/02699052.2019.1641746 UR - https://m2.mtmt.hu/api/publication/30749104 ID - 30749104 N1 - Funding Agency and Grant Number: National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30973440, 30770950]; Chongqing Natural Science Foundation (CSTC)Natural Science Foundation of ChongqingNatural Science Foundation Project of CQ CSTC [2008BA0021, cstc2012jjA0155] Funding text: No potential conflicts of interest relevant to this article are reported. The research was supported by the National Natural Science Foundation of China (No: 30973440, 30770950) and was a key project of Chongqing Natural Science Foundation (CSTC, 2008BA0021, cstc2012jjA0155). AB - A diagnostic accuracy study was adopted to evaluate the ability of Cerebral edema monitor by comparing the index test results with those of the reference standard. The serum levels of astrocyte S100 protein and neuron-specific enolase (NSE) were determined. Changes in the cerebral electrical impedance coefficient (CEIC) was detected with the BORN-BE monitor. The left- and right-sided CEIC values, serum levels of S100, and serum NSE in the CPB group significantly increased from the beginning to the end of the operation (P < .05). Furthermore, left and right-sided CEIC values, serum levels of S100, and serum NSE in the CPB-B group were significantly higher than those of the CPB-A group (P < .05). Detection rates of cerebral edema in the CPB-B group at the 24 h post-operative time point were significantly higher than those in the CPB-A group (P < .05). The degree of brain damage is positively correlated with the CPB and aortic cross-clamping. CEIC is a sensitive index reflecting brain damage during CPB in infants. LA - English DB - MTMT ER - TY - JOUR AU - Li, Xue AU - Sun, Jingjing AU - Mu, Rong AU - Gan, Yuzhou AU - Wang, Guanying AU - He, Jing AU - Yi, Li AU - Wang, Qingwen AU - Sun, Xiaolin AU - Li, Zhanguo TI - The clinical significance of ubiquitin carboxyl hydrolase L1 and its autoantibody in neuropsychiatric systemic lupus erythematosus JF - CLINICAL AND EXPERIMENTAL RHEUMATOLOGY J2 - CLIN EXP RHEUMATOL VL - 37 PY - 2019 IS - 3 SP - 474 EP - 480 PG - 7 SN - 0392-856X UR - https://m2.mtmt.hu/api/publication/30749105 ID - 30749105 N1 - Funding Agency and Grant Number: National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31530020, 81471601, 81671602, 31570880]; Sanming Project of Medicine in Shenzhen [SZSM201612009]; Beijing Nova ProgramBeijing Municipal Science & Technology Commission [Z171100001117025]; Peking University Clinical Medicine + X Project for Joint Investigation of Youth; Peking University People's Hospital Scientific Research Development Funds [RDY2017-05]; Interdisciplinary Medicine Seed Fund of Peking University [BMU2017MX011] Funding text: this work was supported by funds from the National Natural Science Foundation of China (31530020 to Z. Li, 81471601 and 81671602 to X. Sun and 31570880 to J. He), Sanming Project of Medicine in Shenzhen (SZSM201612009 to Q. W. ang, Beijing Nova Program (Z171100001117025 to X. Sun), Peking University Clinical Medicine + X Project for Joint Investigation of Youth, Peking University People's Hospital Scientific Research Development Funds (RDY2017-05 to X. Li) and Interdisciplinary Medicine Seed Fund of Peking University (BMU2017MX011 to X. Li). AB - ObjectiveTo identify specific cerebrospinal fluid (CSF) biomarkers for the diagnosis and disease severity evaluation of neuropsychiatric systemic lupus erythematosus (NPSLE).MethodsPatients presented with neuropsychiatric symptoms were recruited and categorised as 36 NPSLE, 19 SLE controls, 4 other connective tissue disease (CTD) controls and 10 nervous system disorder (NSD) controls. The NPSLE group consisted of severe NPSLE (sNPSLE) and mild NPSLE (mNPSLE). Potential biomarkers were determined by Luminex multiplex assay and enzyme-linked immunosorbent assay.Results1) Among a variety of neurological disease-related proteins, only ubiquitin carboxyl hydrolase L1 (UCH-L1) levels were significantly elevated in the CSF samples of sNPSLE patients compared with those of mNPSLE patients (p=0.020) and SLE controls (p=0.037). CSF UCH-L1 levels were significantly positively correlated with SLE disease activity index and overlap number of NPSLE manifestations. 2) CSF anti-UCH-L1 autoantibodies were significantly elevated in patients with NPSLE in comparison to all of the control groups, with a sensitivity of 53% and a specificity of 91% for NPSLE. CSF anti-UCH-L1 levels were associated with organ involvement and were positively correlated with serum anti-UCH-L1 levels in the NPSLE patients (r=0.4551, p=0.0382).ConclusionAnti-UCH-L1 is a promising CSF biomarker for NPSLE diagnosis with high specificity, and the elevated levels of CSF UCH-L1 reflect the clinical severity of NPSLE. The elevation of UCH-L1 and its autoantibody in NPSLE patients showed us novel aetiological insights on NPSLE. LA - English DB - MTMT ER - TY - JOUR AU - Morris, Mackenzie C. AU - Bercz, Aron AU - Niziolek, Grace M. AU - Kassam, Farzaan AU - Veile, Rose AU - Friend, Lou Ann AU - Pritts, Timothy A. AU - Makley, Amy T. AU - Goodman, Michael D. TI - UCH-L1 is a Poor Serum Biomarker of Murine Traumatic Brain Injury After Polytrauma JF - JOURNAL OF SURGICAL RESEARCH J2 - J SURG RES VL - 244 PY - 2019 SP - 63 EP - 68 PG - 6 SN - 0022-4804 DO - 10.1016/j.jss.2019.06.023 UR - https://m2.mtmt.hu/api/publication/31568798 ID - 31568798 N1 - Funding Agency and Grant Number: NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM008478] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008478] Funding Source: NIH RePORTER AB - Background: Several serum biomarkers have been studied to diagnose incidence and severity of traumatic brain injury (TBI), but a reliable biomarker in TBI has yet to be identified. Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) has been proposed as a biomarker in clinical and preclinical studies, largely in the setting of isolated TBI or concussion. The aim of this study was to evaluate the performance of UGH-L1 as a serum biomarker in the setting of polytrauma and TBI.Methods: Multiple variations of murine TBI and polytrauma models were used to evaluate serum biomarkers. The different models included TBI with and without hemorrhagic shock and resuscitation, isolated extremity vascular ligation, extremity ischemia/reperfusion, and blunt tail injury. Blood was drawn at intervals after injury, and serum levels of neuronspecific enolase, UGH-L1, creatine kinase, and syndecan-1 were evaluated by enzyme-linked immunosorbent assay.Results: UGH-L1 levels were not significantly different between TBI, tail injury, and sham TBI. By contrast, neuron-specific enolase levels were increased in TBI mice compared with tail injury and sham TBI mice. UGH-L1 levels increased regardless of TBI status at 30 min and 4 h after hemorrhagic shock and resuscitation. In mice that underwent femoral artery cannulation followed by hemorrhagic shock/resuscitation, UGH-L1 levels were significantly elevated compared with shock sham mice at 4 h (3158 +/- 2168 pg/mL, 4 h shock versus 0 +/- 0 pg/mL, 4 h shock sham; P < 0.01) and at 24 h (3253 +/- 2954 pg/mL, 24 h shock versus 324 +/- 482 pg/mL, 24 h shock sham; P = 0.03). No differences were observed in UGH-L1 levels between the sham shock and the arterial ligation, vein ligation, or extremity ischemia/reperfusion groups at any time point. Similar to UGH-L1, creatine kinase was elevated only after shock compared with sham mice at 4, 24, and 72 h after injury.Conclusions: Our study demonstrates that UGH-L1 is not a specific marker for TBI but is elevated in models that induce central and peripheral nerve ischemia. Given the increase in UGH-L1 levels observed after hemorrhagic shock, we propose that UGH-L1 may be a useful adjunct in quantifying severity of shock or global ischemia rather than as a specific marker of TBI. (C) 2019 Elsevier Inc. All rights reserved. LA - English DB - MTMT ER - TY - JOUR AU - Posti, Jussi P. AU - Takala, Riikka S. K. AU - Tenovuo, Olli TI - TBIcare Investigators' Response to Papa and Wang (doi: 10:1089/neu.2017.5030): Raising the Bar for Traumatic Brain Injury Biomarker Research: Methods Make a Difference JF - JOURNAL OF NEUROTRAUMA J2 - J NEUROTRAUM VL - 36 PY - 2019 IS - 10 SP - 1680 EP - 1681 PG - 2 SN - 0897-7151 DO - 10.1089/neu.2017.5209 UR - https://m2.mtmt.hu/api/publication/30701648 ID - 30701648 N1 - Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital, Turku, Finland Turku Brain Injury Centre, Turku University Hospital, Turku, Finland Department of Neurology, University of Turku, Turku, Finland Perioperative Services, Intensive Care Medicine and Pain Management, Turku University Hospital and University of Turku, Turku, Finland Export Date: 22 October 2021 CODEN: JNEUE Correspondence Address: Posti, J.P.; Division of Clinical Neurosciences, Finland; email: jussi.posti@utu.fi LA - English DB - MTMT ER - TY - JOUR AU - Quinones-Ossa, G. A. AU - Padilla-Zambrano, H. AU - Pal, R. AU - Ghosh, A. AU - Moscote-Salazar, L. R. AU - Kumar, Kiran V. A. AU - Agrawal, A. TI - Biomarkers in acute brain trauma: A narrative review JF - JOURNAL OF ACUTE DISEASE J2 - J ACUTE DIS VL - 8 PY - 2019 IS - 1 SP - 1 EP - 6 PG - 6 SN - 2221-6189 DO - 10.4103/2221-6189.250370 UR - https://m2.mtmt.hu/api/publication/30487573 ID - 30487573 AB - Biomarkers have been used to diagnose, prognose, evaluate, and identify the severity and outcomes in traumatic brain injury (TBI) patients. This study explored if it is possible to predict the outcome of TBI patients by estimating the biomarkers in cerebrospinal fluid and serum. We searched data bases and literature about biomarkers, and found forty epidemiologic studies from 92 potentially relevant articles. However, limited data are available about postanoxic encephalopathy. It showed that presently, neurofilament, S100B, glial fibrillary acidic protein, and ubiquitin carboxyl terminal hydrolase-L1 seemed to have the best potential as diagnostic biomarkers for distinguishing focal and diffuse injury, whereas C-Tau, neuron-specific enolase, S100B, glial fibrillary acidic protein, and spectrin breakdown products appear to be candidates for reflective biomarkers of TBI. Point-of-care biomarkers are needed in TBI which is one of the most important additional risk factors in road traffic injuries. In a holistic approach, more researches about biomarkers of TBI are required. These biomarkers are very useful for treatment of patients with TBI. LA - English DB - MTMT ER - TY - JOUR AU - Rezaii, Paymon Garakani AU - Grant, Gerald Arthur AU - Zeineh, Michael Maroun AU - Richardson, Kara Janice AU - Coburn, Maria Lynn AU - Bet, Anthony Marco AU - Weber, Art AU - Jiang, Bin AU - Li, Ying AU - Ubungen, Kristine AU - Routh, Gay AU - Wheatcroft, Alex Marie AU - Paulino, Amy Devine AU - Hayes, Ronald Lawrence AU - Steinberg, Gary Kenneth AU - Wintermark, Max TI - Stability of Blood Biomarkers of Traumatic Brain Injury JF - JOURNAL OF NEUROTRAUMA J2 - J NEUROTRAUM VL - 36 PY - 2019 IS - 16 SP - 2407 EP - 2416 PG - 10 SN - 0897-7151 DO - 10.1089/neu.2018.6053 UR - https://m2.mtmt.hu/api/publication/30725890 ID - 30725890 N1 - Department of Radiology, Stanford University, Stanford Medical Center, 300 Pasteur Drive, Stanford, CA 94305-5488, United States Department of Neurosurgery, Stanford University, Stanford, CA, United States Department of Anatomic Pathology and Clinical Laboratories, Stanford University, Stanford, CA, United States Banyan Biomarkers Inc, San Diego, CA, United States Science 37, Los Angeles, CA, United States Cited By :6 Export Date: 13 September 2021 CODEN: JNEUE Correspondence Address: Wintermark, M.; Department of Radiology, 300 Pasteur Drive, United States; email: mwinterm@stanford.edu Export Date: 14 September 2021 CODEN: JNEUE Department of Radiology, Stanford University, Stanford Medical Center, 300 Pasteur Drive, Stanford, CA 94305-5488, United States Department of Neurosurgery, Stanford University, Stanford, CA, United States Department of Anatomic Pathology and Clinical Laboratories, Stanford University, Stanford, CA, United States Banyan Biomarkers Inc, San Diego, CA, United States Science 37, Los Angeles, CA, United States Cited By :6 Export Date: 14 September 2021 CODEN: JNEUE Correspondence Address: Wintermark, M.; Department of Radiology, 300 Pasteur Drive, United States; email: mwinterm@stanford.edu AB - Blood biomarker tests were recently approved for clinical diagnosis of traumatic brain injury (TBI), yet there are still fundamental questions that need attention. One such question is the stability of putative biomarkers in blood over the course of several days after injury if the sample is unable to be processed into serum or plasma and stored at low temperatures. Blood may not be able to be stored at ultra-low temperatures in austere combat or sports environments. In this prospective study of 20 adult patients with positive head computed tomography imaging findings, the stability of three biomarkers (glial fibrillary acidic protein [GFAP], ubiquitin C-terminal hydrolase-L1 [UCH-L1], and S100 calcium binding protein B [S100B]) in whole blood and in serum stored at 4-5 degrees C was evaluated over the course of 72 h after blood collection. The amount of time whole blood and serum were refrigerated had no significant effect on GFAP concentration in plasma obtained from whole blood and in serum (p = 0.6256 and p = 0.3687, respectively), UCH-L1 concentration in plasma obtained from whole blood and in serum (p = 0.0611 and p = 0.5189, respectively), and S100B concentration in serum (p = 0.4663). Concentration levels of GFAP, UCH-L1, and S100B in blood collected from patients with TBI were found to be stable at 4-5 degrees C for at least 3 days after blood draw. This study suggests that the levels of the three diagnostic markers above are still valid for diagnostic TBI tests if the sample is stored in 4-5 degrees C refrigerated conditions. LA - English DB - MTMT ER - TY - JOUR AU - Rubenstein, Richard AU - Sharma, Deep R. AU - Chang, Binggong AU - Oumata, Nassima AU - Came, Morgane AU - Vaucelle, Use AU - Lindberg, Mattias F. AU - Chiu, Allen AU - Wisniewski, Thomas AU - Wang, Kevin K. W. AU - Meijer, Laurent TI - Novel Mouse Tauopathy Model for Repetitive Mild Traumatic Brain Injury: Evaluation of Long-Term Effects on Cognition and Biomarker Levels After Therapeutic Inhibition of Tau Phosphorylation JF - FRONTIERS IN NEUROLOGY J2 - FRONT NEUR VL - 10 PY - 2019 PG - 21 SN - 1664-2295 DO - 10.3389/fneur.2019.00124 UR - https://m2.mtmt.hu/api/publication/30651257 ID - 30651257 N1 - Funding Agency and Grant Number: Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense (DOD) Broad Agency Announcement [W81XWH-14-2-0166]; Fonds Unique Interministeriel (FUI) TRIAD project; Fondation Jerome Lejeune; NIA grant [AG08051]; SUNY Downstate Medical Center; CIFRE/ManRos Therapeutics Ph.D. fellowshipFrench National Research Agency (ANR); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG008051] Funding Source: NIH RePORTER Funding text: The authors would like to thank Dr. Peter Davies for the antitau antibodies. This study is supported in part by the Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense (DOD) Broad Agency Announcement under Award number W81XWH-14-2-0166 (RR). This study was also supported in part by the Fonds Unique Interministeriel (FUI) TRIAD project (LM), Fondation Jerome Lejeune (LM), NIA grant AG08051 (TW) and the SUNY Downstate Medical Center. MC is recipient of a CIFRE/ManRos Therapeutics Ph.D. fellowship. LV is a Master 2 student from the Universite Technologique de Compiegne (UTC). AB - Traumatic brain injury (TBI) is a risk factor for a group of neurodegenerative diseases termed tauopathies, which includes Alzheimer's disease and chronic traumatic encephalopathy (CTE). Although TBI is stratified by impact severity as either mild (m), moderate or severe, mTBI is the most common and the most difficult to diagnose. Tauopathies are pathologically related by the accumulation of hyperphosphorylated tau (P-tau) and increased total tau (T-tau). Here we describe: (i) a novel human tau-expressing transgenic mouse model, TghTau/PS1, to study repetitive mild closed head injury (rmCHI), (ii) quantitative comparison of T-tau and P-tau from brain and plasma in TghTau/PS1 mice over a 12 month period following rmCHI (and sham), (iii) the usefulness of P-tau as an early- and late-stage blood-based biochemical biomarker for rmCHI, (iii) the influence of kinase-targeted therapeutic intervention on rmCHI-associated cognitive deficits using a combination of lithium chloride (UCI) and R-roscovitine (ros), and (iv) correlation of behavioral and cognitive changes with concentrations of the brain and blood-based T-tau and P-tau. Compared to sham-treated mice, behavior changes and cognitive deficits of rrriCHI-treated TghTau/PS1 mice correlated with increases in both cortex and plasma T-tau and P-tau levels over 12 months. In addition, T-tau, but more predominantly P-tau, levels were significantly reduced in the cortex and plasma by LiCI + ros approaching the biomarker levels in sham and drug-treated sham mice (the drugs had only modest effects on the T-tau and P-tau levels in sham mice) throughout the 12 month study period. Furthermore, although we also observed a reversal of the abnormal behavior and cognitive deficits in the drug-treated rmCHI mice (compared to the untreated rmCHI mice) throughout the time course, these drug-treated effects were most pronounced up until 10 and 12 months where the abnormal behavior and cognition deficits began to gradually increase. These studies describe: (a) a translational relevant animal model for TBI-linked tauopathies, and (b) utilization of T-tau and P-tau as rmCHl biomarkers in plasma to monitor novel therapeutic strategies and treatment regimens for these neurodegenerative diseases. LA - English DB - MTMT ER - TY - JOUR AU - Thelin, Eric AU - Al Nimer, Faiez AU - Frostell, Arvid AU - Zetterberg, Henrik AU - Blennow, Kaj AU - Nystrom, Harriet AU - Svensson, Mikael AU - Bellander, Bo-Michael AU - Piehl, Fredrik AU - Nelson, David W. TI - A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury JF - JOURNAL OF NEUROTRAUMA J2 - J NEUROTRAUM VL - 36 PY - 2019 IS - 20 SP - 2850 EP - 2862 PG - 13 SN - 0897-7151 DO - 10.1089/neu.2019.6375 UR - https://m2.mtmt.hu/api/publication/30725729 ID - 30725729 N1 - Cited By :9 Export Date: 8 June 2020 CODEN: JNEUE Correspondence Address: Thelin, E.; Department of Clinical Neuroscience, Karolinska InstitutetSweden; email: eric.thelin@ki.se Chemicals/CAS: protein S100B, 357701-89-4; ubiquitin thiolesterase, 86480-67-3 Funding details: Stockholms Läns Landsting Funding details: Svenska Läkaresällskapet, SLS Funding details: European Research Council, ERC Funding details: Svenska Sällskapet för Medicinsk Forskning, SSMF Funding details: VetenskapsrÃ¥det, VR, 2009-3514-68832-22, 2006-3514-41955-22 Funding details: Knut och Alice Wallenbergs Stiftelse Funding text 1: Support to F.P. for this study was received from the Swedish Research Council (2006-3514-41955-22 and 2009-3514-68832-22). Work in the laboratory of H.Z. and K.B. is supported by grants from the Swedish Research Council, the European Research Council, the Knut and Alice Wallenberg Foundation, Hjärnfonden, Alzheimerfonden, and Swedish State Support for Clinical Research (ALFGBG). H.Z. is a Wallenberg Academy Fellow and is additionally supported by the UK Dementia Research Institute at UCL. K.B. holds the Torsten Söderberg Professorship of Medicine. E.P.T. is funded by post-doc scholarships from the Swedish Society for Medical Research and the Swedish Society of Medicine. D.W.N. was supported by funding from the Stockholm County Council. Cited By :43 Export Date: 13 September 2021 CODEN: JNEUE Correspondence Address: Thelin, E.; Department of Clinical Neuroscience, Sweden; email: eric.thelin@ki.se Cited By :43 Export Date: 14 September 2021 CODEN: JNEUE Correspondence Address: Thelin, E.; Department of Clinical Neuroscience, Sweden; email: eric.thelin@ki.se AB - Brain-enriched protein biomarkers of tissue fate are being introduced clinically to aid in traumatic brain injury (TBI) management. The aim of this study was to determine how concentrations of six different protein biomarkers, measured in samples collected during the first weeks after TBI, relate to injury severity and outcome. We included neurocritical care TBI patients that were prospectively enrolled from 2007 to 2013, all having one to three blood samples drawn during the first 2 weeks. The biomarkers analyzed were S100 calcium-binding protein B (S100B), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1), tau, and neurofilament-light (NF-L). Glasgow Outcome Score (GOS) was assessed at 12 months. In total, 172 patients were included. All serum markers were associated with injury severity as classified on computed tomography scans at admission. Almost all biomarkers outperformed other known outcome predictors with higher levels the first 5 days, correlating with unfavorable outcomes, and UCH-L1 (0.260, pseduo-R-2) displaying the best discrimination in univariate analyses. After adjusting for acknowledged TBI outcome predictors, GFAP and NF-L added most independent information to predict favorable/unfavorable GOS, improving the model from 0.38 to 0.51 pseudo-R-2. A correlation matrix indicated substantial covariance, with the strongest correlation between UCH-L1, GFAP, and tau (r = 0.827-0.880). Additionally, the principal component analysis exhibited clustering of UCH-L1 and tau, as well as GFAP, S100B, and NSE, which was separate from NF-L. In summary, a panel of several different protein biomarkers, all associated with injury severity, with different cellular origin and temporal trajectories, improve outcome prediction models. LA - English DB - MTMT ER - TY - JOUR AU - Wolahan, Stephanie M. AU - Lebby, Elliott AU - Mao, Howard C. AU - McArthur, David AU - Real, Courtney AU - Vespa, Paul AU - Braas, Daniel AU - Glenn, Thomas C. TI - Novel Metabolomic Comparison of Arterial and Jugular Venous Blood in Severe Adult Traumatic Brain Injury Patients and the Impact of Pentobarbital Infusion JF - JOURNAL OF NEUROTRAUMA J2 - J NEUROTRAUM VL - 36 PY - 2019 IS - 2 SP - 212 EP - 221 PG - 10 SN - 0897-7151 DO - 10.1089/neu.2018.5674 UR - https://m2.mtmt.hu/api/publication/30522374 ID - 30522374 N1 - UCLA Brain Injury Research Center and Department of Neurosurgery, David Geffen School of Medicine at UCLA, 300 Stein Plaza, Suite 562, Los Angeles, CA 90095, United States UCLA Metabolomics Center, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States Export Date: 13 May 2019 CODEN: JNEUE Correspondence Address: Wolahan, S.M.; UCLA Brain Injury Research Center and Department of Neurosurgery, David Geffen School of Medicine at UCLA, 300 Stein Plaza, Suite 562, United States; email: SWolahan@mednet.ucla.edu AB - Treatment of severe traumatic brain injury (TBI) in the intensive care unit focuses on controlling intracranial pressure, ensuring sufficient cerebral perfusion, and monitoring for secondary injuries. However, there are limited prognostic tools and no biomarkers or tests of the evolving neuropathology. Metabolomics has the potential to be a powerful tool to indirectly monitor evolving dysfunctional metabolism. We compared metabolite levels in simultaneously collected arterial and jugular venous samples in acute TBI patients undergoing intensive care as well as in healthy control volunteers. Our results show that, first, many circulating metabolites are decreased in TBI patients compared with healthy controls days after injury; both proline and hydroxyproline were depleted by 60% compared with healthy controls, as was gluconate. Second, both arterial and jugular venous plasma metabolomic analysis separates TBI patients from healthy controls and shows that distinct combinations of metabolites are driving the group separation in the two blood types. Third, TBI patients under heavy sedation with pentobarbital at the time of blood collection were discernibly different from patients not receiving pentobarbital. These results highlight the importance of accounting for medications in metabolomics analysis. Jugular venous plasma metabolomics shows potential as a minimally invasive tool to identify and study dysfunctional cerebral metabolism after TBI. LA - English DB - MTMT ER - TY - JOUR AU - Asken, Breton M. AU - Bauer, Russell M. AU - DeKosky, Steven T. AU - Houck, Zachary M. AU - Moreno, Charles C. AU - Jaffee, Michael S. AU - Weber, Arthur G. AU - Clugston, James R. TI - Concussion Biomarkers Assessed in Collegiate Student-Athletes (BASICS) I Normative study JF - NEUROLOGY J2 - NEUROLOGY VL - 91 PY - 2018 IS - 23 SP - E2109 EP - E2122 PG - 14 SN - 0028-3878 DO - 10.1212/WNL.0000000000006613 UR - https://m2.mtmt.hu/api/publication/30529128 ID - 30529128 N1 - Funding Agency and Grant Number: GE; Banyan Biomarkers, Inc.; U.S. Army Medical Research and Material Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-06-1-0517]; NFL; University of FloridaUniversity of Florida Funding text: This work was primarily supported by funds provided in a grant from the Head Health Initiative, a collaboration between GE and the NFL, Banyan Biomarkers, Inc., and the U.S. Army Medical Research and Material Command (USAMRMC) under contract W81XWH-06-1-0517. The University of Florida owns stock in Banyan Biomarkers, Inc., which is the sponsor of the study. In addition, the university has licensed technology to Banyan concerning blood biomarkers or proteins thereby allowing Banyan to use the technology. The company is interested in making a biomarker test for traumatic brain injury. If the biomarker test is sold commercially, then the University of Florida could benefit financially. Please feel free to ask any further questions you might have about this matter. AB - Objective LA - English DB - MTMT ER - TY - JOUR AU - Awad, Hamdy AU - Essandoh, Michael TI - Goal-Directed Oxygen Delivery During Cardiopulmonary Bypass: Can This Perfusion Strategy Improve Biochemical and Clinical Neurologic Outcomes? JF - JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA J2 - J CARDIOTHOR VASC AN VL - 32 PY - 2018 IS - 6 SP - 2493 EP - 2494 PG - 2 SN - 1053-0770 DO - 10.1053/j.jvca.2018.07.052 UR - https://m2.mtmt.hu/api/publication/30529129 ID - 30529129 N1 - Cited By :2 Export Date: 22 October 2021 CODEN: JCVAE LA - English DB - MTMT ER - TY - JOUR AU - Chen, Li-Xiong AU - Zhang, Wei-Feng AU - Wang, Ming AU - Jia, Pi-Feng TI - Relationship of calcitonin gene-related peptide with disease progression and prognosis of patients with severe traumatic brain injury JF - NEURAL REGENERATION RESEARCH J2 - NEUR REG RES VL - 13 PY - 2018 IS - 10 SP - 1782 EP - 1786 PG - 5 SN - 1673-5374 DO - 10.4103/1673-5374.238619 UR - https://m2.mtmt.hu/api/publication/30528945 ID - 30528945 N1 - Department of Critical Care Medicine, North Hospital of Ruijin Hospital, Shanghai, China Department of Neurosurgery, North Hospital of Ruijin Hospital, Shanghai, China Cited By :4 Export Date: 21 October 2021 Correspondence Address: Jia, P.-F.; Department of Neurosurgery, China; email: Jiapifeng@sina.com AB - Calcitonin gene-related peptide (CGRP) has been implicated in multiple functions across many bioprocesses; however, whether CGRP is associated with severe traumatic brain injury (TBI) remains poorly understood. In this study, 96 adult patients with TBI (enrolled from September 2015 to December 2016) were divided into a mild/moderate TBI group (36 males and 25 females, aged 38 +/- 13 years) and severe TBI group (22 males and 13 females, aged 38 +/- 11 years) according to Glasgow Coma Scale scores. In addition, 25 healthy individuals were selected as controls (15 males and 10 females, aged 39 +/- 13 years). Radioimmunoassay was used to detect serum levels of CGRP and endothelin-1 at admission and at 12, 24, 48, 72 hours, and 7 days after admission. CGRP levels were remarkably lower, but endothelin-1 levels were obviously higher in the severe TBI group compared with mild/moderate TBI and control groups. Levels of CGRP were remarkably lower, but endothelin-1 levels were obviously higher in deceased patients compared with patients who survived. Survival analysis and logistic regression showed that both CGRP and endothelin-1 levels were associated with patient mortality, with each serving as an independent risk factor for 6-month mortality of severe TBI patients. Moreover, TBI patients with lower serum CGRP levels had a higher risk of death. Thus, our retrospective analysis demonstrates the potential utility of CGRP as a new biomarker, monitoring method, and therapeutic target for TBI. LA - English DB - MTMT ER - TY - JOUR AU - Chmielewska, N AU - Szyndler, J AU - Makowska, K AU - Wojtyna, D AU - Maciejak, P AU - Płaźnik, A TI - Looking for novel, brain-derived, peripheral biomarkers of neurological disorders JF - NEUROLOGIA I NEUROCHIRURGIA POLSKA J2 - NEUROL NEUROCHIR POL VL - 52 PY - 2018 IS - 3 SP - 318 EP - 325 PG - 8 SN - 0028-3843 DO - 10.1016/j.pjnns.2018.02.002 UR - https://m2.mtmt.hu/api/publication/27669184 ID - 27669184 N1 - Funding Agency and Grant Number: National Science Centre, PolandNational Science Centre, Poland [2014/13/B/NZ7/02277]; European Union - The European Regional Development Fund within the operational program "Innovative economy'' for 2007-2013 Funding text: This study was supported by Grant No. 2014/13/B/NZ7/02277 from the National Science Centre, Poland.; Project implemented with CePT infrastructure financed by the European Union - The European Regional Development Fund within the operational program "Innovative economy'' for 2007-2013. LA - English DB - MTMT ER - TY - JOUR AU - Du, Quan AU - Weng, Jian-Feng AU - Luo, Li-Feng AU - Cen, Meng AU - Yu, Wen-Hua AU - Zheng, Yong-Ke AU - Hu, Wei AU - Pan, Jian-Wei AU - Dong, Xiao-Qiao TI - Serum ST2 as a potential prognostic biomarker for traumatic brain injury JF - CLINICA CHIMICA ACTA J2 - CLIN CHIM ACTA VL - 487 PY - 2018 SP - 145 EP - 152 PG - 8 SN - 0009-8981 DO - 10.1016/j.cca.2018.09.035 UR - https://m2.mtmt.hu/api/publication/30529131 ID - 30529131 N1 - Funding Agency and Grant Number: International Cooperation Project of Zhejiang Provincial Science and Technology Department [2015C34007]; Zhejiang Province Medical and Health Fund Project [2014KYA177, 2016RCB016]; Hangzhou Medical Research Fund Project [2014Z06, 2016Z10]; Ningbo Medical Research Fund Project [2016A12]; Hangzhou science and technology Fund project [20180533843] Funding text: The authors thank all staffs in Department of Neurosurgery, The CHC International Hospital (Cixi, China) for their technical support. This study was supported financially by the International Cooperation Project of Zhejiang Provincial Science and Technology Department (No.2015C34007), Zhejiang Province Medical and Health Fund Project (No. 2014KYA177, 2016RCB016), Hangzhou Medical Research Fund Project (No. 2014Z06, 2016Z10), Ningbo Medical Research Fund Project (No. 2016A12) and Hangzhou science and technology Fund project (No. 20180533843). AB - Background: ST2, a receptor of interleukin-33, is involved in inflammation. We discerned the relationship between serum soluble ST2 (sST2) concentrations, inflammation, severity and prognosis following traumatic brain injury (TBI). LA - English DB - MTMT ER - TY - JOUR AU - Hellewell, Sarah C AU - Mondello, Stefania AU - Conquest, Alison AU - Shaw, Gerry AU - Madorsky, Irina AU - Deng, Jay V AU - Little, Lorraine AU - Kobeissy, Firas AU - Bye, Nicole AU - Bellomo, Rinaldo AU - Cooper, David J AU - Vallance, Shirley AU - Board, Jasmine AU - Morganti-Kossmann, Maria C TI - Erythropoietin Does Not Alter Serum Profiles of Neuronal and Axonal Biomarkers After Traumatic Brain Injury: Findings From the Australian EPO-TBI Clinical Trial JF - CRITICAL CARE MEDICINE J2 - CRIT CARE MED VL - 46 PY - 2018 IS - 4 SP - 554 EP - 561 PG - 8 SN - 0090-3493 DO - 10.1097/CCM.0000000000002938 UR - https://m2.mtmt.hu/api/publication/27341898 ID - 27341898 N1 - Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, Canada Department of Surgery, Alfred Hospital, Melbourne, Australia Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina University, Messina, Italy EnCor Biotechnology Inc., Gainesville, FL, United States Australian New Zealand Intensive Care Research Centre, Melbourne, Australia Department of Psychiatry and Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, United States Department of Intensive Care Research, Austin Health, Melbourne, Australia Department of Intensive Care, Alfred Hospital, Melbourne, Australia Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia Department of Child Health, Barrow Neurological Institute, University of Arizona, Phoenix, AZ, United States Cited By :12 Export Date: 21 October 2021 CODEN: CCMDC LA - English DB - MTMT ER - TY - JOUR AU - Hughes, Christopher G AU - Patel, Mayur B AU - Brummel, Nathan E AU - Thompson, Jennifer L AU - McNeil, J Brennan AU - Pandharipande, Pratik P AU - Jackson, James C AU - Chandrasekhar, Rameela AU - Ware, Lorraine B AU - Ely, E Wesley AU - Girard, Timothy D TI - Relationships between markers of neurologic and endothelial injury during critical illness and long-term cognitive impairment and disability JF - INTENSIVE CARE MEDICINE J2 - INTENS CARE MED VL - 44 PY - 2018 IS - 3 SP - 345 EP - 355 PG - 11 SN - 0342-4642 DO - 10.1007/s00134-018-5120-1 UR - https://m2.mtmt.hu/api/publication/27341894 ID - 27341894 N1 - Funding Agency and Grant Number: CTSA award from the National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TR000445]; National Institutes on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG027472, AG045085]; American Geriatrics Society Jahnigen Career Development Award; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [TR000445, AG027472, AG045085, HL111111, GM120484, TR00046, AG040549, AG035117, HL103836, HL112656, AG034257, HL135144]; Vanderbilt Faculty Research Scholars Program; VA Clinical Science Research and Development Service; Veterans Affairs Tennessee Valley Geriatric Research, Education and Clinical Center; Vanderbilt Clinical and Translational Scholars Program; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [R13TR000046, UL1TR000445] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL111111, K24HL103836, R21HL112656, R01HL135144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM120484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R03AG045085, R01AG035117, K23AG034257, R01AG027472, K76AG054864] Funding Source: NIH RePORTER Funding text: This project was supported by CTSA award TR000445 from the National Center for Advancing Translational Sciences and by the National Institutes on Aging (AG027472 and AG045085). In addition, Dr. Hughes received support from American Geriatrics Society Jahnigen Career Development Award and the National Institutes of Health (HL111111, AG045085, GM120484), Dr. Patel received support from the National Institutes of Health (HL111111, GM120484) and the Vanderbilt Faculty Research Scholars Program, Dr. Brummel received support from the National Institutes of Health TR00046 and AG040549 and by the Vanderbilt Clinical and Translational Scholars Program, Dr. Pandharipande received support from the National Institutes of Health (AG027472, HL111111, GM120484), Dr. Ely received support from the VA Clinical Science Research and Development Service and the National Institutes of Health (AG027472, AG035117, HL111111, GM120484), Dr. Ware received support from the National Institutes of Health (HL103836 and HL112656), and Dr. Girard received support from the National Institutes of Health (AG034257, AG035117, HL135144). Drs. Ely and Girard also received support from the Veterans Affairs Tennessee Valley Geriatric Research, Education and Clinical Center. We used REDCap, a secure online database, supported in part by the National Institutes of Health TR000445. LA - English DB - MTMT ER - TY - JOUR AU - Ilginel, M.T. AU - Tunay, D.L. AU - Güneş, Y. TI - Biomarkers in traumatic brain injury JF - ANESTEZI DERGESI J2 - ANESTEZI DERGESI VL - 26 PY - 2018 IS - 3 SP - 105 EP - 119 PG - 15 SN - 1300-0578 UR - https://m2.mtmt.hu/api/publication/32464248 ID - 32464248 N1 - Export Date: 21 October 2021 CODEN: ADNEC Correspondence Address: Ilginel, M.T.; Çukurova University Faculty of Medicine, TMT Park Life Sit. C Blok Kat 3 Daire 6, Turkey; email: muratilginel.02@hotmail.com LA - Turkish DB - MTMT ER - TY - CHAP AU - Kawata, Keisuke AU - Tierney, Ryan AU - Langford, Dianne ED - Stern, RA ED - Hainline, B TI - Blood and cerebrospinal fluid biomarkers T2 - SPORTS NEUROLOGY SN - 9780444639554 ; 9780444639547 PY - 2018 SP - 217 EP - 233 PG - 17 DO - 10.1016/B978-0-444-63954-7.00022-7 UR - https://m2.mtmt.hu/api/publication/31406431 ID - 31406431 N1 - Export Date: 19 August 2020 Cited By :5 Export Date: 10 March 2021 Correspondence Address: Langford, D.; Lewis Katz School of Medicine at Temple University, 3500 North Broad Street, United States; email: tdl@temple.edu AB - Sports-related traumatic brain injuries (TBIs) range in severity from severe to subconcussive. Although technologies exist for clinical diagnosis of more severe injuries, methods for diagnosis of milder forms of brain injury are limited. Developing objective measures to indicate pathogenic processes after a suspected mild TBI is challenging for multiple reasons. The field of biomarker discovery for diagnosing TBI continues to expand, with newly identified candidate biomarkers being reported regularly. Brain-specific biomarkers include proteins derived from neurons and glia, and are often measured to assess neural injury and repair, and to predict outcomes. Ideally, changes in biomarker levels should indicate pathologic events and answer critical questions for accurate diagnosis and prognosis. For example, does the presence or a change in the biomarker level suggest greater vulnerability for sustaining a second concussion or show that the window of increased vulnerability has passed? Likewise, do changes in biomarker levels predict postconcussion syndrome or recovery/repair? Although there are numerous promising candidates for fluid biomarkers that may diagnose mild TBI or concussion, none has reached the clinic to date. In this chapter, we will define biomarkers, discuss the importance of understanding their normal and pathologic functions, and outline some considerations for interpreting detection assay results in TBI. We will then review five proposed blood and cerebrospinal fluid biomarkers (tau, neurofilament, ubiquitin carboxyl-terminal hydrolase L1, S100 beta, and glial fibrillary acidic protein) used currently to address TBI. Lastly, we will discuss a future trajectory for developing new, clinically useful fluid biomarkers. LA - English DB - MTMT ER - TY - JOUR AU - Ko, J. AU - Hemphill, M. AU - Yang, Z. AU - Sewell, E. AU - Na, Y. J. AU - Sandsmark, D. K. AU - Haber, M. AU - Fisher, S. A. AU - Torre, E. A. AU - Svane, K. C. AU - Omelchenko, A. AU - Firestein, B. L. AU - Diaz-Arrastia, R. AU - Kim, J. AU - Meaney, D. F. AU - Issadore, D. TI - Diagnosis of traumatic brain injury using miRNA signatures in nanomagnetically isolated brain-derived extracellular vesicles JF - LAB ON A CHIP J2 - LAB CHIP VL - 18 PY - 2018 IS - 23 SP - 3617 EP - 3630 PG - 14 SN - 1473-0197 DO - 10.1039/c8lc00672e UR - https://m2.mtmt.hu/api/publication/30529133 ID - 30529133 N1 - Funding Agency and Grant Number: New Jersey Commission on Brain Injury Research [CSCR14IRG005]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 088276]; Allen Foundation [U01 NS086090]; Pennsylvania Department of Health Commonwealth Universal Research Enhancement Program, the National Institute of Health [1R21CA182336-01A1]; American Cancer Society - CEOs Against Cancer - CA Division Research Scholar GrantAmerican Cancer Society [RSG-15-227-01-CSM]; National Science Foundation's CAREER Award [1554200]; Hartwell Individual Research Award; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA182336, R33CA206907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH118170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090] Funding Source: NIH RePORTER Funding text: We thank Tawny Meredith-Duliba and Erika Silverman from the Diaz-Arrastia lab at Penn for collecting and processing clinical samples that were used for this study. Funding was provided by the New Jersey Commission on Brain Injury Research (CSCR14IRG005) to DI, DM, and BF, NIH NS 088276 to DM, Allen Foundation to DM and DI, U01 NS086090 to RDA, the Pennsylvania Department of Health Commonwealth Universal Research Enhancement Program, the National Institute of Health: 1R21CA182336-01A1 to DI and JK, and DI was supported by an American Cancer Society - CEOs Against Cancer - CA Division Research Scholar Grant, (RSG-15-227-01-CSM), the National Science Foundation's CAREER Award (#1554200), and The Hartwell Individual Research Award. AB - The accurate diagnosis and clinical management of traumatic brain injury (TBI) is currently limited by the lack of accessible molecular biomarkers that reflect the pathophysiology of this heterogeneous disease. To address this challenge, we developed a microchip diagnostic that can characterize TBI more comprehensively using the RNA found in brain-derived extracellular vesicles (EVs). Our approach measures a panel of EV miRNAs, processed with machine learning algorithms to capture the state of the injured and recovering brain. Our diagnostic combines surface marker-specific nanomagnetic isolation of brain-derived EVs, biomarker discovery using RNA sequencing, and machine learning processing of the EV miRNA cargo to minimally invasively measure the state of TBI. We achieved an accuracy of 99% identifying the signature of injured vs. sham control mice using an independent blinded test set (N = 77), where the injured group consists of heterogeneous populations (injury intensity, elapsed time since injury) to model the variability present in clinical samples. Moreover, we successfully predicted the intensity of the injury, the elapsed time since injury, and the presence of a prior injury using independent blinded test sets (N = 82). We demonstrated the translatability in a blinded test set by identifying TBI patients from healthy controls (AUC = 0.9, N = 60). This approach, which can detect signatures of injury that persist across a variety of injury types and individual responses to injury, more accurately reflects the heterogeneity of human TBI injury and recovery than conventional diagnostics, opening new opportunities to improve treatment of traumatic brain injuries. LA - English DB - MTMT ER - TY - JOUR AU - Kornguth, Steven AU - Rutledge, Neal TI - Integration of Biomarkers Into a Signature Profile of Persistent Traumatic Brain Injury Involving Autoimmune Processes Following Water Hammer Injury From Repetitive Head Impacts JF - BIOMARKER INSIGHTS J2 - BIOMARKER INSIGHTS VL - 13 PY - 2018 PG - 8 SN - 1177-2719 DO - 10.1177/1177271918808216 UR - https://m2.mtmt.hu/api/publication/30528943 ID - 30528943 N1 - Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, United States Department of Neurology, Dell Medical School, The University of Texas at Austin, United States Department of Psychology, The University of Texas at Austin and Austin Radiological Association, Austin, TX, United States Cited By :5 Export Date: 10 September 2021 Correspondence Address: Kornguth, S.; Department of Kinesiology and Health Education, United States; email: steve_kornguth@utexas.edu AB - OBJECTIVES: To assemble an algorithm that will describe a "Signature" predictive of an individual's vulnerability to persistent traumatic brain injury (TBI) LA - English DB - MTMT ER - TY - JOUR AU - Metzger, Ryan R. AU - Sheng, Xiaoming AU - Niedzwecki, Christian M. AU - Bennett, Kimberly S. AU - Morita, Denise C. AU - Zielinski, Brandon AU - Schober, Michelle E. TI - Temporal response profiles of serum ubiquitin C-terminal hydrolase-L1 and the 145-kDa alpha II-spectrin breakdown product after severe traumatic brain injury in children JF - JOURNAL OF NEUROSURGERY - PEDIATRICS J2 - J NEUROS-PEDIATR VL - 22 PY - 2018 IS - 4 SP - 369 EP - 374 PG - 6 SN - 1933-0707 DO - 10.3171/2018.4.PEDS17593 UR - https://m2.mtmt.hu/api/publication/30483411 ID - 30483411 N1 - Funding Agency and Grant Number: Primary Children's Hospital Foundation Integrated Science Award; University of Utah Clinical and Translational Sciences [CTSA 5UL1RR025764-01] Funding text: This study was supported by a Primary Children's Hospital Foundation Integrated Science Award (all authors) and by the University of Utah Clinical and Translational Sciences (grant no. CTSA 5UL1RR025764-01; Dr. Metzger). Study data were collected and managed using REDCap (Research Electronic Data Capture) tools hosted at the University of Utah.15 Cited By :2 Export Date: 19 February 2021 AB - OBJECTIVE Traumatic brain injury (TBI) is the leading cause of acquired disability among children. Brain injury biomarkers may serve as useful diagnostic and prognostic indicators for TBI. Levels of ubiquitin C-terminal hydrolase-L1 (UCH-L1) and the 145-kDa alpha II-spectrin breakdown product (SBDP-145) correlate with outcome in adults after severe TBI. The authors conducted a pilot study of these biomarkers in children after severe TBI to inform future research exploring their utility in this population. LA - English DB - MTMT ER - TY - JOUR AU - Najem, Dema AU - Rennie, Kerry AU - Ribecco-Lutkiewicz, Maria AU - Dao, Ly AU - Haukenfrers, Julie AU - Liu, Qing AU - Nzau, Munyao AU - Fraser, Douglas D AU - Bani-Yaghoub, Mahmud TI - Traumatic brain injury: classification, models, and markers JF - BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE J2 - BIOCHEM CELL BIOL VL - 96 PY - 2018 IS - 4 SP - 391 EP - 406 PG - 16 SN - 0829-8211 DO - 10.1139/bcb-2016-0160 UR - https://m2.mtmt.hu/api/publication/27604646 ID - 27604646 N1 - Department of Translational Bioscience, National Research Council Canada, Ottawa, ON K1A 0R6, Canada Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada Paediatric Neurosurgery, Children's Hospital of Eastern Ontario, Ottawa, ON K1H 8L1, Canada Children's Health Research Institute, London, ON N6C 2V5, Canada Departments of Pediatrics and Clinical Neurological Sciences, Western University, London, ON N6A 3K7, Canada Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada C2-C82, Childrens Hospital, London Health Sciences Centre, 800 Commissioners Road East, London, ON N6A 5W9, Canada Cited By :18 Export Date: 10 September 2021 CODEN: BCBIE Correspondence Address: Fraser, D.D.; Children's Health Research InstituteCanada; email: douglas.fraser@lhsc.on.ca Export Date: 14 September 2021 CODEN: BCBIE LA - English DB - MTMT ER - TY - JOUR AU - Patila, Uday P. AU - Mally, Pradeep V. AU - Wachtel, Elena V. TI - Serum biomarkers of neuronal injury in newborns evaluated for selective head cooling: a comparative pilot study JF - JOURNAL OF PERINATAL MEDICINE J2 - J PERINAT MED VL - 46 PY - 2018 IS - 8 SP - 942 EP - 947 PG - 6 SN - 0300-5577 DO - 10.1515/jpm-2017-0354 UR - https://m2.mtmt.hu/api/publication/30521951 ID - 30521951 N1 - Department of Pediatrics, Division of Neonatology, Icahn School of Medicine at Mount Sinai, Elmhurst Hospital Center, 79-01 Broadway, A7-34, Elmhurst, NY, United States Department of Pediatrics, Division of Neonatology, New York University School of Medicine, New York, NY, United States Cited By :2 Export Date: 20 February 2020 CODEN: JPEMA Correspondence Address: Patil, U.P.; Department of Pediatrics, Division of Neonatology, Icahn School of Medicine at Mount Sinai, Elmhurst Hospital Center, 79-01 Broadway, A7-34, United States; email: uday.patil@mssm.edu Department of Pediatrics, Division of Neonatology, Icahn School of Medicine at Mount Sinai, Elmhurst Hospital Center, 79-01 Broadway, A7-34, Elmhurst, NY, United States Department of Pediatrics, Division of Neonatology, New York University School of Medicine, New York, NY, United States Cited By :2 Export Date: 17 August 2020 CODEN: JPEMA Correspondence Address: Patil, U.P.; Department of Pediatrics, Division of Neonatology, Icahn School of Medicine at Mount Sinai, Elmhurst Hospital Center, 79-01 Broadway, A7-34, United States; email: uday.patil@mssm.edu AB - Background: Evaluation of newborns for hypoxic ischemic encephalopathy (HIE) includes laboratory and clinical parameters, as well as amplitude integrated electroencephalogram (aEEG). Based on qualifying criteria, selective head cooling (SHC) is initiated for infants with evidence of moderate to severe HIE. However, some newborns may not qualify for hypothermia therapy based on normal aEEG. LA - English DB - MTMT ER - TY - JOUR AU - Shahjouei, Shima AU - Sadeghi-Naini, Mohsen AU - Yang, Zhihui AU - Kobeissy, Firas AU - Rathore, Disa AU - Shokraneh, Farhad AU - Blackburn, Spiros AU - Manley, Geoff T AU - Wang, Kevin K W TI - The diagnostic values of UCH-L1 in traumatic brain injury: A meta-analysis JF - BRAIN INJURY J2 - BRAIN INJURY VL - 32 PY - 2018 IS - 1 SP - 1 EP - 17 PG - 17 SN - 0269-9052 DO - 10.1080/02699052.2017.1382717 UR - https://m2.mtmt.hu/api/publication/27350288 ID - 27350288 N1 - Funding Agency and Grant Number: DODUnited States Department of Defense [W81XWH-14-2-0176]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1U01 NS086090-01, R21 NS085455-01] Funding text: This work was supported by the DOD [W81XWH-14-2-0176]; NIH [1U01 NS086090-01], NIH [R21 NS085455-01]. Cited By :10 Export Date: 9 September 2021 CODEN: BRAIE Correspondence Address: Wang, K.K.W.; Department of Neurosurgery, Qarib St, Keshavarz Blvd, Iran; email: kwang@ufl.edu LA - English DB - MTMT ER - TY - JOUR AU - Siahaan, AMP AU - Japardi, I AU - Hakim, AA TI - Serum concentration of ubiquitin c-terminal hydrolase-L1 in detecting severity of traumatic brain injury JF - IOP CONFERENCE SERIES: EARTH AND ENVIRONMENTAL SCIENCE J2 - IOP CONF SER EARTH AND ENVIRON SCI VL - 125 PY - 2018 SN - 1755-1307 DO - 10.1088/1755-1315/125/1/012207 UR - https://m2.mtmt.hu/api/publication/27465976 ID - 27465976 LA - English DB - MTMT ER - TY - JOUR AU - Singh, GP AU - Nigam, R AU - Tomar, GS AU - Monisha, M AU - Bhoi, SK AU - Arulselvi, S AU - Sengar, K AU - Akula, D AU - Panta, P AU - Anindya, R TI - Early and rapid detection of UCHL1 in the serum of brain-trauma patients: A novel gold nanoparticle-based method for diagnosing the severity of brain injury JF - ANALYST J2 - ANALYST VL - 143 PY - 2018 IS - 14 SP - 3366 EP - 3373 PG - 8 SN - 0003-2654 DO - 10.1039/c8an00533h UR - https://m2.mtmt.hu/api/publication/27466040 ID - 27466040 N1 - Funding Agency and Grant Number: Department of Biotechnology, Ministry of Science & Technology, Government of IndiaDepartment of Biotechnology (DBT) India [BT/PR14412/NNT/28/849/2015] Funding text: The work was funded by Extra-mural research project (No. BT/PR14412/NNT/28/849/2015), Department of Biotechnology, Ministry of Science & Technology, Government of India. LA - English DB - MTMT ER - TY - JOUR AU - Toliczenko-Bernatowicz, Dorota AU - Matuszczak, Ewa AU - Tylicka, Marzena AU - Szymanska, Beata AU - Komarowska, Marta AU - Gorodkiewicz, Ewa AU - Debek, Wojciech AU - Hermanowicz, Adam TI - Overexpression of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in boys with cryptorchidism JF - PLOS ONE J2 - PLOS ONE VL - 13 PY - 2018 IS - 2 PG - 10 SN - 1932-6203 DO - 10.1371/journal.pone.0191806 UR - https://m2.mtmt.hu/api/publication/27341895 ID - 27341895 N1 - Paediatric Surgery Department, Medical University of Bialystok, Bialystok, Poland Biophysics Department, Medical University of Bialystok, Bialystok, Poland Electrochemistry Department, University of Bialystok, Bialystok, Poland Cited By :6 Export Date: 21 October 2021 CODEN: POLNC Correspondence Address: Matuszczak, E.; Paediatric Surgery Department, Poland; email: ewamat@tlen.pl LA - English DB - MTMT ER - TY - JOUR AU - Wang, Kevin K AU - Yang, Zhihui AU - Zhu, Tian AU - Shi, Yuan AU - Rubenstein, Richard AU - Tyndall, J Adrian AU - Manley, Geoff T TI - An update on diagnostic and prognostic biomarkers for traumatic brain injury JF - EXPERT REVIEW OF MOLECULAR DIAGNOSTICS J2 - EXPERT REV MOL DIAGN VL - 18 PY - 2018 IS - 2 SP - 165 EP - 180 PG - 16 SN - 1473-7159 DO - 10.1080/14737159.2018.1428089 UR - https://m2.mtmt.hu/api/publication/27350296 ID - 27350296 N1 - Program for Neurotrauma, Neuroproteomics & Biomarkers Research, Departments of Emergency Medicine, Psychiatry, Neuroscience and Chemistry, University of Florida, Gainesville, FL, United States Department Of Pediatrics, Daping Hospital, Chongqing, Third Military Medical University, Chongqing, China Laboratory of Neurodegenerative Diseases and CNS Biomarker Discovery, Departments of Neurology and Physiology/Pharmacology, SUNY Downstate Medical Center, Brooklyn, NY, United States Department of Emergency Medicine, University of Florida, Gainesville, FL, United States Brain and Spinal Injury Center, San Francisco General Hospital, San Francisco, CA, United States Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, United States Cited By :111 Export Date: 10 September 2021 CODEN: ERMDC Correspondence Address: Wang, K.K.; Program for Neurotrauma, United States; email: kawangwang17@gmail.com LA - English DB - MTMT ER - TY - CHAP AU - Azar, S AU - Hasan, A AU - Younes, R AU - Najdi, F AU - Baki, L AU - Ghazale, H AU - Kobeissy, FH AU - Zibara, K AU - Mondello, S ED - Kobeissy, Firas H. ED - Stevens,, Stanley M. TI - Biofluid proteomics and biomarkers in traumatic brain injury T2 - Neuroproteomics PB - Springer New York CY - New York, New York SN - 9781493969524 T3 - Methods in Molecular Biology, ISSN 1064-3745 ; 1598. PY - 2017 SP - 45 EP - 63 PG - 19 DO - 10.1007/978-1-4939-6952-4_3 UR - https://m2.mtmt.hu/api/publication/27466045 ID - 27466045 N1 - Export Date: 19 August 2020 Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon Department of Mechanical and Industrial Engineering, Qatar University, Doha, Qatar Biomedical Engineering and Department of Mechanical Engineering, American University of Beirut, Beirut, 1107 2020, Lebanon Center for Biomedical Engineering, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, United States Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, United States Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon Department of Psychiatry, Center for Neuroproteomics and Biomarkers Research, University of Florida, Gainesville, FL, United States Department of Biomedical, Odontoiatric and Morphological and Functional Imaging Sciences, University of Messina, A.O.U. “Policlinico G. Martino”, Via Consolare Valeria, Messina, 98125, Italy Cited By :15 Export Date: 10 March 2021 Correspondence Address: Mondello, S.; Department of Biomedical, Via Consolare Valeria, Italy; email: stm_mondello@hotmail.com LA - English DB - MTMT ER - TY - JOUR AU - Dey, Subir AU - Gangadharan, Jagathlal AU - Deepika, Akhil AU - Kumar, J Keshav AU - Christopher, Rita AU - Ramesh, Shruthi S AU - Devi, B Indira AU - Shukla, Dhaval P TI - Correlation of ubiquitin C terminal hydrolase and S100 beta with cognitive deficits in young adults with mild traumatic brain injury JF - NEUROLOGY INDIA J2 - NEUROL INDIA VL - 65 PY - 2017 IS - 4 SP - 761 EP - 766 PG - 6 SN - 0028-3886 DO - 10.4103/neuroindia.NI_884_15 UR - https://m2.mtmt.hu/api/publication/26771596 ID - 26771596 N1 - Funding Agency and Grant Number: "NEUROCON" fund Funding text: Subir Dey received a grant for this study from "NEUROCON2011" fund. The other authors report no declarations of interest. Export Date: 19 August 2020 CODEN: NURYA Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka 560 029, India Department of Clinical Neurosciences, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India Department of Clinical Psychology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India Department of Neurochemistry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India Cited By :9 Export Date: 10 March 2021 CODEN: NURYA Correspondence Address: Shukla, D.P.; Department of Neurosurgery, India; email: neurodhaval@rediffmail.com LA - English DB - MTMT ER - TY - JOUR AU - Ding, Yongbo AU - Shi, Cunxian AU - Chen, Linjing AU - Ma, Piliang AU - Li, Kezhong AU - Jin, Jin AU - Zhang, Qingfeng AU - Li, Aizhi TI - Effects of andrographolide on postoperative cognitive dysfunction and the association with NF-kappa B/MAPK pathway JF - ONCOLOGY LETTERS J2 - ONCOL LETT VL - 14 PY - 2017 IS - 6 SP - 7367 EP - 7373 PG - 7 SN - 1792-1074 DO - 10.3892/ol.2017.7088 UR - https://m2.mtmt.hu/api/publication/27103670 ID - 27103670 N1 - Department of Anesthesiology, School of Medicine, Shandong University, Jinan, Shandong 250012, China Department of Anesthesiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, China Department of Operating Room, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, China Department of Anesthesiology, Qingdao Hiser Medical Center, Qingdao, Shandong 266033, China Cited By :17 Export Date: 22 October 2021 Correspondence Address: Shi, C.; Department of Anesthesiology, 20 Yuhuangding East Road, Zhifu, China; email: shicunxian@163.com LA - English DB - MTMT ER - TY - JOUR AU - Geeraerts, T AU - Velly, L AU - Abdennour, L AU - Asehnoune, K AU - Audibert, G AU - Bouzat, P AU - Bruder, N AU - Carrillon, R AU - Cottenceau, V AU - Cotton, F AU - Courtil-Teyssedre, S AU - Dahyot-Fizelier, C AU - Dailler, F AU - David, J-S AU - Engrand, N AU - Fletcher, D AU - Francony, G AU - Gergelé, L AU - Ichai, C AU - Javouhey, É AU - Leblanc, P-E AU - Lieutaud, T AU - Meyer, P AU - Mirek, S AU - Orliaguet, G AU - Proust, F AU - Quintard, H AU - Ract, C AU - Srairi, M AU - Tazarourte, K AU - Vigué, B AU - Payen, J-F TI - Management of severe traumatic brain injury (first 24 hours) JF - JOURNAL EUROPEEN DES URGENCES ET DE REANIMATION J2 - JOURNAL EUROPEEN DES URGENCES ET DE REANIMATION VL - 29 PY - 2017 IS - 2 SP - 167 EP - 192 PG - 26 SN - 2211-4238 DO - 10.1016/j.jeurea.2017.04.007 UR - https://m2.mtmt.hu/api/publication/27466043 ID - 27466043 N1 - Pôle anesthésie-réanimation, CHU de Toulouse, Toulouse, 31059, France Service d'anesthésie-réanimation, hôpital de la Timone, Assistance publique–Hôpitaux de Marseille, Marseille, 13000, France Département d'anesthésie-réanimation, groupe hospitalier Pitié-Salpêtrière, AP–HP, Paris, 75013, France Service d'anesthésie et de réanimation chirurgicale, Hôtel-Dieu, CHU de Nantes, Nantes, 44093, France Département d'anesthésie-réanimation, hôpital Central, CHU de Nancy, Nancy, 54000, France Pôle anesthésie-réanimation, CHU Grenoble Alpes, Grenoble, 38043, France Service d'anesthésie-réanimation, hôpital neurologique Pierre-Wertheimer, groupement hospitalier Est, Hospices civils de Lyon, Bron, 69677, France Service de réanimation chirurgicale et traumatologique, SAR 1, hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France Service d'imagerie, centre hospitalier Lyon Sud, hospices civils de Lyon, Pierre-Bénite cedex, 69495, France Service de réanimation pédiatrique, hôpital femme-mère-enfant, hospices civils de Lyon, Bron, 69677, France Département d'anesthésie-réanimation, CHU de Poitiers, Poitiers cedex, 86021, France Service d'anesthésie réanimation, centre hospitalier Lyon Sud, hospices civils de Lyon, Pierre-Bénite, 69495, France Service d'anesthésie-réanimation, fondation ophtalmologique Adolphe de Rothschild, Paris, 75940, France Service d'anesthésie réanimation chirurgicale, hôpital Raymond-Poincaré, AP–HP, université de Versailles St-Quentin, Garches, France Département d'anesthésie réanimation, centre hospitalier universitaire de Saint-Etienne, Saint-Etienne, 42055, France Service de réanimation polyvalente, CHU de Nice, Nice, 06000, France Département d'anesthésie-réanimation, hôpitaux universitaires Paris-Sud, université Paris-Sud, hôpital de Bicêtre, AP–HP, Le Kremlin-Bicêtre, France Centre hospitalier de Bourg-en-Bresse, centre de recherche en neurosciences, université Claude-Bernard de Lyon, France Service d'anesthésie réanimation, hôpital universitaire Necker–Enfants-Malades, université Paris-Descartes, AP–HP, Paris, 75743, France Département d'anesthésie réanimation, CHU de Dijon, Dijon, France Service de neurochirurgie, CHU de Strasbourg, hôpital Hautepierre, Strasbourg, 67098, France Service des urgences, SAMU/SMUR, hospices civils de Lyon, hôpital Édouard-Herriot, Lyon, 69437, France Export Date: 10 September 2021 Correspondence Address: Geeraerts, T.; Pôle anesthésie-réanimation, France; email: geeraerts.t@chu-toulouse.fr LA - French DB - MTMT ER - TY - CHAP AU - Glushakova, OY AU - Glushakov, AV AU - Mannix, R AU - Miller, ER AU - Valadka, AB AU - Hayes, RL TI - The Use of Blood-Based Biomarkers to Improve the Design of Clinical Trials of Traumatic Brain Injury T2 - Handbook of Neuroemergency Clinical Trials: Second Edition PB - Elsevier Inc. SN - 9780128041017 PB - Elsevier Inc. PY - 2017 SP - 139 EP - 166 PG - 28 DO - 10.1016/B978-0-12-804064-5.00008-4 UR - https://m2.mtmt.hu/api/publication/27465687 ID - 27465687 N1 - Virginia Commonwealth University School of Medicine, Richmond, VA, United States University of Florida College of Medicine, Gainesville, FL, United States Harvard Medical School, Boston, MA, United States Banyan Biomarkers, Inc., Alachua, FL, United States Cited By :7 Export Date: 9 September 2021 Correspondence Address: Glushakova, O.Y.; Virginia Commonwealth University School of MedicineUnited States LA - English DB - MTMT ER - TY - JOUR AU - Gul, S S AU - Huesgen, K W AU - Wang, K K AU - Mark, K AU - Tyndall, J A TI - Prognostic utility of neuroinjury biomarkers in post out-of-hospital cardiac arrest (OHCA) patient management JF - MEDICAL HYPOTHESES J2 - MED HYPOTHESES VL - 105 PY - 2017 SP - 34 EP - 47 PG - 14 SN - 0306-9877 DO - 10.1016/j.mehy.2017.06.016 UR - https://m2.mtmt.hu/api/publication/26938869 ID - 26938869 N1 - Department of Emergency Medicine, University of Florida, 1329, SW 16th Street, Suite 5270, Gainesville, FL 32608, United States Program for Neurotrauma, Neuroproteomics & Biomarker Research, Department of Psychiatry, McKnight Brain Institute, University of Florida, 1149 Newell Drive, Gainesville, FL 32610, United States Cited By :15 Export Date: 21 October 2021 CODEN: MEHYD Correspondence Address: Tyndall, J.A.; Department of Emergency Medicine, 1329, SW 16th Street, Suite 5270, United States; email: tyndall@ufl.edu LA - English DB - MTMT ER - TY - BOOK AU - Jain, K.K. TI - The handbook of biomarkers PB - Springer New York CY - New York, New York PY - 2017 SP - 1 EP - 760 SP - 760 SN - 9781493974306 DO - 10.1007/9781493974313 UR - https://m2.mtmt.hu/api/publication/34496720 ID - 34496720 N1 - Export Date: 11 January 2024 LA - English DB - MTMT ER - TY - JOUR AU - Lewis, Lawrence M AU - Schloemann, Derek T AU - Papa, Linda AU - Fucetola, Robert P AU - Bazarian, Jeffrey AU - Lindburg, Miranda AU - Welch, Robert D TI - Utility of Serum Biomarkers in the Diagnosis and Stratification of Mild Traumatic Brain Injury JF - ACADEMIC EMERGENCY MEDICINE J2 - ACAD EMERG MED VL - 24 PY - 2017 IS - 6 SP - 710 EP - 720 PG - 11 SN - 1069-6563 DO - 10.1111/acem.13174 UR - https://m2.mtmt.hu/api/publication/26771613 ID - 26771613 N1 - Division of Emergency Medicine, Washington University School of Medicine, Saint Louis, MO, United States Department of Neurology, Washington University School of Medicine, Saint Louis, MO, United States Department of Emergency Medicine, Orlando Regional Medical Center, Orlando, FL, United States Department of Emergency Medicine, University of Rochester School of Medicine, Rochester, NY, United States Department of Emergency Medicine, Wayne State University, Detroit, MI, United States Cited By :35 Export Date: 22 October 2021 CODEN: AEMEF Correspondence Address: Lewis, L.M.; Division of Emergency Medicine, United States; email: lewisl@wustl.edu LA - English DB - MTMT ER - TY - JOUR AU - Lorente, Leonardo TI - Biomarkers Associated with the Outcome of Traumatic Brain Injury Patients JF - BRAIN SCIENCES J2 - BRAIN SCI VL - 7 PY - 2017 IS - 11 PG - 11 SN - 2076-3425 DO - 10.3390/brainsci7110142 UR - https://m2.mtmt.hu/api/publication/27103672 ID - 27103672 N1 - Funding Agency and Grant Number: Instituto de Salud Carlos III (Madrid, Spain)Instituto de Salud Carlos III [INT16/00165]; Fondo Europeo de Desarrollo Regional (FEDER)European Commission Funding text: This study was supported by a grant from Instituto de Salud Carlos III (INT16/00165) (Madrid, Spain) and co-financed by Fondo Europeo de Desarrollo Regional (FEDER). Cited By :23 Export Date: 13 September 2021 Correspondence Address: Lorente, L.; Intensive Care Unit, Spain; email: lorentemartin@msn.com LA - English DB - MTMT ER - TY - JOUR AU - Posti, Jussi P AU - Hossain, Iftakher AU - Takala, Riikka S K AU - Liedes, Hilkka AU - Newcombe, Virginia AU - Outtrim, Joanne AU - Katila, Ari J AU - Frantzen, Janek AU - Ala-Seppala, Henna AU - Coles, Jonathan P AU - Kyllonen, Anna AU - Maanpaa, Henna-Riikka AU - Tallus, Jussi AU - Hutchinson, Peter J AU - van Gils, Mark AU - Menon, David K AU - Tenovuo, Olli AU - TBIcare, Investigators TI - Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 Are Not Specific Biomarkers for Mild CT-Negative Traumatic Brain Injury JF - JOURNAL OF NEUROTRAUMA J2 - J NEUROTRAUM VL - 34 PY - 2017 IS - 7 SP - 1427 EP - 1438 PG - 12 SN - 0897-7151 DO - 10.1089/neu.2016.4442 UR - https://m2.mtmt.hu/api/publication/26584142 ID - 26584142 N1 - Group Author: TBIcare Investigators Megjegyzés-26584141 Group Author: TBIcare Investigators Megjegyzés-26584140 Group Author: TBIcare Investigators LA - English DB - MTMT ER - TY - CHAP AU - Ramadan, Naify AU - Ghazale, Hussein AU - El-Sayyad, Mohammad AU - El-Haress, Mohamad AU - Kobeissy, Firas H. ED - Kobeissy, Firas H. ED - Stevens,, Stanley M. TI - Neuroproteomics Studies: Challenges and Updates T2 - Neuroproteomics PB - Springer New York CY - New York, New York SN - 9781493969524 T3 - Methods in Molecular Biology, ISSN 1064-3745 ; 1598. PY - 2017 SP - 3 EP - 19 PG - 17 DO - 10.1007/978-1-4939-6952-4_1 UR - https://m2.mtmt.hu/api/publication/31882281 ID - 31882281 N1 - Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon Department of Family Medicine, University of Toledo, Toledo, OH, United States Faculty of Medicine, Beirut Arab University, Beirut, Lebanon Department of Psychiatry, Center for Neuroproteomics and Biomarkers Research, University of Florida, Gainesville, FL, United States Cited By :8 Export Date: 22 October 2021 Correspondence Address: Kobeissy, F.H.; Department of Biochemistry and Molecular Genetics, Lebanon; email: firasko@gmail.com AB - The Human Genome Project in 2003 has resulted in the complete sequence of similar to 99% of the human genome paving the road for the Human Proteome Project (HPP) assessing the full characterization of the translated protein map of the 20,300 protein-coding genes. Consequently, the emerging of the proteomics field has successfully been adopted as the method of choice for the proteome characterization. Proteomics is a term that is used to encompass multidisciplinary approaches combining different technologies that aim to study the entire spectrum of protein changes at a specific physiological condition. Proteomics research has shown excellent outcomes in different fields, among which is neuroscience; however, the complexity of the nervous systems necessitated the genesis of a new subdiscipline of proteomics termed as "neuroproteomics." Neuroproteomics studies involve assessing the quantitative and qualitative aspects of nervous system components encompassing global dynamic events underlying various brain-related disorders ranging from neuropsychiatric disorders, degenerative disorders, mental illness, and most importantly brain-specific neurotrauma-related injuries. In this introductory chapter, we will provide a brief historical perspective on the field of neuroproteomics. In doing so, we will highlight on the recent applications of neuroproteomics in the areas of neurotrauma, an area that has benefitted from neuroproteomics in terms of biomarker research, spatiotemporal injury mechanism, and its use to translate its findings from experimental settings to human translational applications. Importantly, this chapter will include some recommendation to the general studies in the area of neuroproteomics and the need to move from this field from being a descriptive, hypothesis-free approach to being an independent mature scientific discipline. LA - English DB - MTMT ER - TY - JOUR AU - Sharma, K AU - Stevens, RD TI - Determinants of prognosis in neurocatastrophes JF - HANDBOOK OF CLINICAL NEUROLOGY J2 - HANDB CLIN NEUROL VL - 140 PY - 2017 SP - 379 EP - 395 PG - 17 SN - 0072-9752 DO - 10.1016/B978-0-444-63600-3.00021-0 UR - https://m2.mtmt.hu/api/publication/27466044 ID - 27466044 LA - English DB - MTMT ER - TY - JOUR AU - Thelin, EP AU - Zeiler, FA AU - Ercole, A AU - Mondello, S AU - Büki, András AU - Bellander, BM AU - Helmy, A AU - Menon, DK AU - Nelson, DW TI - Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain injury Dynamics: A Systematic Review JF - FRONTIERS IN NEUROLOGY J2 - FRONT NEUR VL - 8 PY - 2017 PG - 23 SN - 1664-2295 DO - 10.3389/fneur.2017.00300 UR - https://m2.mtmt.hu/api/publication/3248575 ID - 3248575 N1 - Funding Agency and Grant Number: Swedish Society of Medicine [SLS-587221]; Cambridge Commonwealth Trust Scholarship; Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery; University of Manitoba Clinician Investigator Program, R. Samuel McLaughlin Research and Education Award; Manitoba Medical Service Foundation; University of Manitoba Faculty of Medicine Dean's Fellowship Fund; Hungarian Brain Research Program [KTIA_13_NAP-A-II/8]; National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award; European Union Framework Program 7 grant [602150]; Medical Research Council; Cambridge Biomedical Research Centre; Royal College of Surgeons of England; National Institute for Health Research [NF-SI-0512-10090] Funding Source: researchfish Funding text: The following funding should be acknowledged: ET: Swedish Society of Medicine (Grant no. SLS-587221). FZ: Cambridge Commonwealth Trust Scholarship, the Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery, the University of Manitoba Clinician Investigator Program, R. Samuel McLaughlin Research and Education Award, the Manitoba Medical Service Foundation, and the University of Manitoba Faculty of Medicine Dean's Fellowship Fund. AB: Hungarian Brain Research Program-Grant No. KTIA_13_NAP-A-II/8. DM: National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award to DM. The authors were also supported by a European Union Framework Program 7 grant (CENTER-TBI; Grant Agreement No. 602150). AH: Medical Research Council, Cambridge Biomedical Research Centre, Royal College of Surgeons of England. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. LA - English DB - MTMT ER - TY - JOUR AU - Vio, Valentina AU - Jose, Marchant Maria AU - Araya, Eyleen AU - Kogan, Marcelo J TI - Metal Nanoparticles for the Treatment and Diagnosis of Neurodegenerative Brain Diseases JF - CURRENT PHARMACEUTICAL DESIGN J2 - CURR PHARM DESIGN VL - 23 PY - 2017 IS - 13 SP - 1916 EP - 1926 PG - 11 SN - 1381-6128 DO - 10.2174/1381612823666170105152948 UR - https://m2.mtmt.hu/api/publication/26757897 ID - 26757897 N1 - Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Chile ICBM, Facultad de Medicina, Universidad de Chile, Chile Laboratorio de Química Biológica, Instituto de Química, Facultad de Ciencias, Pontificia Universidad Católica de Valparaíso, Chile Advanced Center for Chronic Diseases, Chile Departamento de Ciencias Quimicas, Facultad de Ciencias Exactas, Universidad Andres Bello, Republica 275, Santiago, Chile Cited By :18 Export Date: 22 October 2021 CODEN: CPDEF Correspondence Address: Araya, E.; The Departamento de Quimica Farmacologica y Toxicologica, Chile; email: mkogan@ciq.uchile.cl LA - English DB - MTMT ER - TY - JOUR AU - Ydens, Elke AU - Palmers, Ilse AU - Hendrix, Sven AU - Somers, Veerle TI - The Next Generation of Biomarker Research in Spinal Cord Injury JF - MOLECULAR NEUROBIOLOGY J2 - MOL NEUROBIOL VL - 54 PY - 2017 IS - 2 SP - 1482 EP - 1499 PG - 18 SN - 0893-7648 DO - 10.1007/s12035-016-9757-x UR - https://m2.mtmt.hu/api/publication/26539415 ID - 26539415 N1 - Cited By :11 Export Date: 2 October 2020 CODEN: MONBE Correspondence Address: Somers, V.; Biomedical Research Institute and Transnationale Universiteit Limburg, School of Life Sciences, Diepenbeek, Hasselt University, Martelarenlaan 42, Belgium; email: veerle.somers@uhasselt.be Funding Agency and Grant Number: Research Foundation Flanders (FWO Vlaanderen), Hasselt University; Transnationale Universiteit Limburg; Agency for Innovation by Science and Technology (IWT)Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT) Funding text: This study is supported by Research Foundation Flanders (FWO Vlaanderen), Hasselt University, and the Transnationale Universiteit Limburg. I. Palmers is supported by a doctoral fellowship of the Agency for Innovation by Science and Technology (IWT). Cited By :12 Export Date: 19 February 2021 CODEN: MONBE Cited By :12 Export Date: 10 September 2021 CODEN: MONBE Correspondence Address: Somers, V.; Biomedical Research Institute and Transnationale Universiteit Limburg, Martelarenlaan 42, Belgium; email: veerle.somers@uhasselt.be LA - English DB - MTMT ER - TY - JOUR AU - Zhang, Dan AU - Han, Song AU - Wang, Shizun AU - Luo, Yanlin AU - Zhao, Li AU - Li, Junfa TI - cPKC gamma-mediated down-regulation of UCHL1 alleviates ischaemic neuronal injuries by decreasing autophagy via ERK-mTOR pathway JF - JOURNAL OF CELLULAR AND MOLECULAR MEDICINE J2 - J CELL MOL MED VL - 21 PY - 2017 IS - 12 SP - 3641 EP - 3657 PG - 17 SN - 1582-1838 DO - 10.1111/jcmm.13275 UR - https://m2.mtmt.hu/api/publication/27103669 ID - 27103669 N1 - Cited By :24 Export Date: 22 December 2022 Correspondence Address: Zhao, L.; Department of Neurobiology and Center of Stroke, China; email: zhaoli@ccmu.edu.cn LA - English DB - MTMT ER - TY - JOUR AU - Zheng, Yong-Ke AU - Dong, Xiao-Qiao AU - Du, Quan AU - Wang, Hao AU - Yang, Ding-Bo AU - Zhu, Qiang AU - Che, Zhi-Hao AU - Shen, Yong-Feng AU - Jiang, Li AU - Hu, Wei AU - Wang, Ke-Yi AU - Yu, Wen-Hua TI - Comparison of plasma copeptin and multiple biomarkers for assessing prognosis of patients with aneurysmal subarachnoid hemorrhage JF - CLINICA CHIMICA ACTA J2 - CLIN CHIM ACTA VL - 475 PY - 2017 SP - 64 EP - 69 PG - 6 SN - 0009-8981 DO - 10.1016/j.cca.2017.10.009 UR - https://m2.mtmt.hu/api/publication/27103671 ID - 27103671 N1 - Funding Agency and Grant Number: Zhejiang Province Medical and Health Project; Hangzhou Medical Research Fund Project Funding text: The authors thank all staffs in Department of Neurosurgery, the Hangzhou First Peoples Hospital (Hangzhou, China) for their technical support. This study was supported financially by Zhejiang Province Medical and Health Project and Hangzhou Medical Research Fund Project. LA - English DB - MTMT ER - TY - JOUR AU - Adrian, Harel AU - Marten, Kvist AU - Salla, Nuutinen AU - Lasse, Valimaa TI - Biomarkers of Traumatic Brain Injury: Temporal Changes in Body Fluids JF - ENEURO J2 - ENEURO VL - 3 PY - 2016 IS - 6 PG - 13 SN - 2373-2822 DO - 10.1523/ENEURO.0294-16.2016 UR - https://m2.mtmt.hu/api/publication/26412732 ID - 26412732 N1 - Cited By :34 Export Date: 10 September 2021 Correspondence Address: Adrian, H.; Medicortex Finland Oy, Itäinen Pitkäkatu 4 B, Finland; email: adrian.harel@medicortex.fi LA - English DB - MTMT ER - TY - JOUR AU - Boutte, Angela M AU - Deng-Bryant, Ying AU - Johnson, David AU - Tortella, Frank C AU - Dave, Jitendra R AU - Shear, Deborah A AU - Schmid, Kara E TI - Serum Glial Fibrillary Acidic Protein Predicts Tissue Glial Fibrillary Acidic Protein Break-Down Products and Therapeutic Efficacy after Penetrating Ballistic-Like Brain Injury JF - JOURNAL OF NEUROTRAUMA J2 - J NEUROTRAUM VL - 33 PY - 2016 IS - 1 SP - 147 EP - 156 PG - 10 SN - 0897-7151 DO - 10.1089/neu.2014.3672 UR - https://m2.mtmt.hu/api/publication/25327721 ID - 25327721 N1 - Cited By :13 Export Date: 10 September 2021 CODEN: JNEUE Correspondence Address: Boutté, A.M.; Brain Trauma Neuroprotection and Neurorestoration Branch, 503 Robert Grant Avenue, United States; email: angela.m.boutte.civ@mail.mil LA - English DB - MTMT ER - TY - JOUR AU - Dambinova, Svetlana A AU - Maroon, Joseph C AU - Sufrinko, Alicia M AU - Mullins, John David AU - Alexandrova, Eugenia V AU - Potapov, Alexander A TI - Functional, structural, and neurotoxicity Biomarkers in integrative assessment of Concussions JF - FRONTIERS IN NEUROLOGY J2 - FRONT NEUR VL - 7 PY - 2016 PG - 12 SN - 1664-2295 DO - 10.3389/fneur.2016.00172 UR - https://m2.mtmt.hu/api/publication/26239291 ID - 26239291 N1 - Brain Biomarkers Research Laboratory, DeKalb Medical Center, Decatur, GA, United States Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, United States Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, United States Surgery, Piedmont Hospital, Atlanta, GA, United States Neurotrauma, Burdenko Neurosurgery Institute, Moscow, Russian Federation Cited By :11 Export Date: 22 October 2021 Correspondence Address: Dambinova, S.A.; Brain Biomarkers Research Laboratory, United States; email: dambinova@aol.com LA - English DB - MTMT ER - TY - CHAP AU - Danny, Hsu S-T TI - Folding dynamics and structural basis of the enzyme mechanism of ubiquitin C-terminal hydroylases T2 - Understanding enzymes : function, design, engineering, and analysis PB - Pan Stanford Publishing CY - Boca Raton, Florida SN - 9789814669337 PB - Pan Stanford Publishing PY - 2016 SP - 167 EP - 202 PG - 36 DO - 10.4032/9789814669337 UR - https://m2.mtmt.hu/api/publication/26476677 ID - 26476677 N1 - Cited By :5 Export Date: 22 October 2021 Correspondence Address: Danny Hsu, S.-T.; Institute of Biological Chemistry, 128, Section 2, Academia Road, Taiwan; email: sthsu@gate.sinica.edu.tw LA - English DB - MTMT ER - TY - JOUR AU - Fink, Ericka L AU - Berger, Rachel P AU - Clark, Robert S B AU - Watson, R Scott AU - Angus, Derek C AU - Panigrahy, Ashok AU - Richichi, Rudolph AU - Callaway, Clifton W AU - Bell, Michael J AU - Mondello, Stefania AU - Hayes, Ronald L AU - Kochanek, Patrick M TI - Exploratory study of serum ubiquitin carboxyl-terminal esterase L1 and glial fibrillary acidic protein for outcome prognostication after pediatric cardiac arrest JF - RESUSCITATION J2 - RESUSCITATION VL - 101 PY - 2016 SP - 65 EP - 70 PG - 6 SN - 0300-9572 DO - 10.1016/j.resuscitation.2016.01.024 UR - https://m2.mtmt.hu/api/publication/25967719 ID - 25967719 N1 - Funding Agency and Grant Number: NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12 HD047349]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23 NS065132]; Laerdal Foundation; Banyan Biomarkers, Inc.; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 RR024153, UL1TR000005]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS065132] Funding Source: NIH RePORTER Funding text: NICHD K12 HD047349 (E.L.F.), NINDS K23 NS065132 (E.L.F.), the Laerdal Foundation (E.L.F.), and Banyan Biomarkers, Inc. (E.L.F.). The project described was supported by the National Institutes of Health through grant numbers UL1 RR024153 and UL1TR000005. Banyan Biomarkers, Inc. performed all biomarker measurements without charge. LA - English DB - MTMT ER - TY - JOUR AU - Geeraerts, Thomas AU - Velly, Lionel AU - Abdennour, Lamine AU - Asehnoune, Karim AU - Audibert, Gerard AU - Bouzat, Pierre AU - Bruder, Nicolas AU - Carrillon, Romain AU - Cottenceau, Vincent AU - Cotton, Francois AU - Courtil-Teyssedre, Sonia AU - Dahyot-Fizelier, Claire AU - Dailler, Frederic AU - David, Jean-Stephane AU - Engrand, Nicolas AU - Fletcher, Dominique AU - Francony, Gilles AU - Gergele, Laurent AU - Ichai, Carole AU - Javouhey, Etienne AU - Leblanc, Pierre-Etienne AU - Lieutaud, Thomas AU - Meyer, Philippe AU - Mirek, Sebastien AU - Orliaguet, Gilles AU - Proust, Francois AU - Quintard, Herve AU - Ract, Catherine AU - Srairi, Mohamed AU - Tazarourte, Karim AU - Vigue, Bernard AU - Payen, Jean-Francois TI - Management of severe traumatic brain injury (first 24 hours) JF - ANESTHESIE REANIMATION URGENCES J2 - ANESTHESIE REANIMATION URGENCES VL - 2 PY - 2016 IS - 6 SP - 431 EP - 453 PG - 23 SN - 2352-5800 DO - 10.1016/j.anrea.2016.09.007 UR - https://m2.mtmt.hu/api/publication/27641256 ID - 27641256 LA - French DB - MTMT ER - TY - JOUR AU - Ghoshal, Sarbani AU - Bondada, Vimala AU - Saatman, Kathryn E AU - Guttmann, Rodney P AU - Geddes, James W TI - Phage display for identification of serum biomarkers of traumatic brain injury JF - JOURNAL OF NEUROSCIENCE METHODS J2 - J NEUROSCI METH VL - 272 PY - 2016 SP - 33 EP - 37 PG - 5 SN - 0165-0270 DO - 10.1016/j.jneumeth.2016.04.026 UR - https://m2.mtmt.hu/api/publication/26405227 ID - 26405227 N1 - Funding Agency and Grant Number: NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS084088, P30 NS051220]; Kentucky Spinal Cord and Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R21NS084088] Funding Source: NIH RePORTER Funding text: This research was supported by NIH grants R21 NS084088 and P30 NS051220 and by the Kentucky Spinal Cord and Head Injury Research Trust. We thank Kathleen Schoch, Ph.D. for the TBI surgeries. LA - English DB - MTMT ER - TY - JOUR AU - Gordillo-Escobar, E AU - Egea-Guerrero, J J AU - Rodriguez-Rodriguez, A AU - Murillo-Cabezas, F TI - Usefulness of biomarkers in the prognosis of severe head injuries JF - MEDICINA INTENSIVA J2 - MED INTENSIVA VL - 40 PY - 2016 IS - 2 SP - 105 EP - 112 PG - 8 SN - 0210-5691 DO - 10.1016/j.medin.2015.11.008 UR - https://m2.mtmt.hu/api/publication/25796335 ID - 25796335 N1 - Cited By :11 Export Date: 21 October 2021 CODEN: MDINE Correspondence Address: Egea-Guerrero, J.J.; Neurocritical Care Unit, Spain; email: jjegeaguererro@gmail.com LA - Spanish DB - MTMT ER - TY - JOUR AU - Graham, Ernest M AU - Burd, Irina AU - Everett, Allen D AU - Northington, Frances J TI - Blood Biomarkers for Evaluation of Perinatal Encephalopathy JF - FRONTIERS IN PHARMACOLOGY J2 - FRONT PHARMACOL VL - 7 PY - 2016 PG - 12 SN - 1663-9812 DO - 10.3389/fphar.2016.00196 UR - https://m2.mtmt.hu/api/publication/26050017 ID - 26050017 N1 - Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States Neuroscience Intensive Care Nursery Program, Johns Hopkins University School of Medicine, Baltimore, MD, United States Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States Integrated Research Center for Fetal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States Division of Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States Division of Neonatology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States Cited By :17 Export Date: 20 February 2020 Correspondence Address: Graham, E.M.; Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of MedicineUnited States; email: egraham5@jhmi.edu Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States Neuroscience Intensive Care Nursery Program, Johns Hopkins University School of Medicine, Baltimore, MD, United States Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States Integrated Research Center for Fetal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States Division of Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States Division of Neonatology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States Cited By :19 Export Date: 14 August 2020 Correspondence Address: Graham, E.M.; Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of MedicineUnited States; email: egraham5@jhmi.edu Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States Neuroscience Intensive Care Nursery Program, Johns Hopkins University School of Medicine, Baltimore, MD, United States Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States Integrated Research Center for Fetal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States Division of Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States Division of Neonatology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States Cited By :26 Export Date: 23 August 2021 Correspondence Address: Graham, E.M.; Division of Maternal-Fetal Medicine, United States; email: egraham5@jhmi.edu LA - English DB - MTMT ER - TY - CHAP AU - Jaber, Zaynab AU - Aouad, Patrick AU - Al, Medawar Mohamad AU - Bahmad, Hisham AU - Abou-Abbass, Hussein AU - Ghandour, Hiba AU - Mondello, Stefania AU - Kobeissy, Firas ED - Mondello, S ED - Hayes, RL ED - Dixon, CE ED - Kobeissy, F TI - Role of Systems Biology in Brain Injury Biomarker Discovery: Neuroproteomics Application T2 - INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS SN - 9781493938162 ; 9781493938148 PY - 2016 SP - 157 EP - 174 PG - 18 DO - 10.1007/978-1-4939-3816-2_10 UR - https://m2.mtmt.hu/api/publication/31406435 ID - 31406435 N1 - Export Date: 19 August 2020 Cited By :8 Export Date: 10 March 2021 AB - Years of research in the field of neurotrauma have led to the concept of applying systems biology as a tool for biomarker discovery in traumatic brain injury (TBI). Biomarkers may lead to understanding mechanisms of injury and recovery in TBI and can be potential targets for wound healing, recovery, and increased survival with enhanced quality of life. The literature available on neurotrauma studies from both animal and clinical studies has provided rich insight on the molecular pathways and complex networks of TBI, elucidating the proteomics of this disease for the discovery of biomarkers. With such a plethora of information available, the data from the studies require databases with tools to analyze and infer new patterns and associations. The role of different systems biology tools and their use in biomarker discovery in TBI are discussed in this chapter. LA - English DB - MTMT ER - TY - JOUR AU - Kiiski, Heikki AU - Tenhunen, Jyrki AU - Ala-Peijari, Marika AU - Huhtala, Heini AU - Hamalainen, Mari AU - Langsjo, Jaakko AU - Moilanen, Eeva AU - Narkilahti, Susanna AU - Ohman, Juha AU - Peltola, Jukka TI - Increased plasma UCH-L1 after aneurysmal subarachnoid hemorrhage is associated with unfavorable neurological outcome JF - JOURNAL OF THE NEUROLOGICAL SCIENCES J2 - J NEUROL SCI VL - 361 PY - 2016 SP - 144 EP - 149 PG - 6 SN - 0022-510X DO - 10.1016/j.jns.2015.12.046 UR - https://m2.mtmt.hu/api/publication/25796336 ID - 25796336 N1 - Funding Agency and Grant Number: Academy of FinlandAcademy of FinlandEuropean Commission [123233, 139345]; Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital Funding text: The study was financially supported by Academy of Finland (Grants 123233, 139345) and the Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital. LA - English DB - MTMT ER - TY - JOUR AU - Korley, Frederick K AU - Diaz-Arrastia, Ramon AU - Wu, Alan H B AU - Yue, John K AU - Manley, Geoffrey T AU - Sair, Haris I AU - Van, Eyk Jennifer AU - Everett, Allen D AU - Okonkwo, David O AU - Valadka, Alex B AU - Gordon, Wayne A AU - Maas, Andrew I R AU - Mukherjee, Pratik AU - Yuh, Esther L AU - Lingsma, Hester F AU - Puccio, Ava M AU - Schnyer, David M AU - TRACK-TBI, Investigators TI - Circulating Brain-Derived Neurotrophic Factor Has Diagnostic and Prognostic Value in Traumatic Brain Injury JF - JOURNAL OF NEUROTRAUMA J2 - J NEUROTRAUM VL - 33 PY - 2016 IS - 2 SP - 215 EP - 225 PG - 11 SN - 0897-7151 DO - 10.1089/neu.2015.3949 UR - https://m2.mtmt.hu/api/publication/25442179 ID - 25442179 N1 - Funding Agency and Grant Number: NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090, RC2NS069409] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [HHSN268201000032C] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090, RC2NS069409] Funding Source: NIH RePORTER LA - English DB - MTMT ER -